Method for producing heteroaryl-substituted phenyltetrahydroisoquinoline compound

A safer and cost-effective method for producing heteroaryl-substituted phenyltetrahydroisoquinoline compounds addresses industrial production challenges by using safer materials and optimizing purification, facilitating large-scale production of high-purity compounds.

WO2026235087A1PCT designated stage Publication Date: 2026-11-12TAISHO PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2026/017059
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-04-30
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing methods for producing heteroaryl-substituted phenyltetrahydroisoquinoline compounds, such as compound [1], face safety and cost challenges due to the use of hazardous materials and inefficient purification processes, making them unsuitable for industrial mass production.

Method used

A modified production method that uses safer starting materials and avoids silica gel column chromatography by converting compound [3-a] to compound [3-b] and then to compound [3-d], and racemizes unwanted enantiomers of compound [2-c] to [2-a] for reuse, optimizing the process for industrial scale production.

Benefits of technology

The new method enhances safety and reduces costs, enabling efficient industrial production of high-purity heteroaryl-substituted phenyltetrahydroisoquinoline compounds suitable for therapeutic applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2026017059_12112026_PF_FP_ABST
    Figure JP2026017059_12112026_PF_FP_ABST
Patent Text Reader

Abstract

With the present invention, it is possible to provide a method for producing a heteroaryl-substituted phenyltetrahydroisoquinoline compound represented by formula (1), a pharmaceutically acceptable salt thereof, or a solvate of these, said production method involving conversion from an optically active compound represented by formula (2-b).
Need to check novelty before this filing date? Find Prior Art

Description

Method for producing heteroaryl-substituted phenyltetrahydroisoquinoline compounds

[0001] The present invention relates to a method for producing heteroaryl-substituted phenyltetrahydroisoquinoline compounds that are useful as compounds having inhibitory activity against sodium / proton exchange transporter 3 (Na+ / H+ exchanger 3, Natrium Hydrogen Exchanger 3, hereinafter also referred to as "NHE3"). The present invention also relates to a novel intermediate compound produced in this production process.

[0002] Constipation and pyelonephrosis refer to a condition characterized by a decrease in the frequency and volume of bowel movements, and pain or difficulty in defecating stool. It is estimated that the frequency of pyelonephrosis is increasing due to changes in diet, lack of exercise, stressful social life with time constraints, and the aging of the population.

[0003] Ingested food is digested in the stomach and small intestine, and its nutrients are mainly absorbed in the small intestine. After that, undigested intestinal contents are sent from the small intestine to the large intestine. In the large intestine, water is absorbed and the stool solidifies, moving towards the anus through peristalsis, and reaching the sigmoid colon where it is stored. When the stored stool flows into the rectum through a contraction called mass peristalsis, the rectal wall stretches, and this stimulus is transmitted to the defecation center in the spinal cord, triggering the defecation reflex, which causes relaxation of the anal sphincter and contraction of the rectum. At the same time, the cerebrum recognizes this as the urge to defecate, and abdominal pressure is increased voluntarily, resulting in defecation. However, if the autonomic nervous system function, motor function, or defecation reflex function of the lower gastrointestinal tract declines due to aging, changes in diet, or lack of exercise, or if excessive water absorption or decreased intestinal fluid secretion in the intestinal tract is induced, constipation can develop.

[0004] Most people with constipation often self-treat with over-the-counter medications or folk remedies because, despite the discomfort, it rarely significantly disrupts their daily lives. However, constipation not only reduces quality of life, but it can also cause systemic ailments, and when constipation arises as a symptom of a systemic disease, the importance of treating it has been emphasized.

[0005] Constipation can be classified into organic constipation and functional constipation based on its cause. Organic constipation is caused by obstruction of the digestive tract due to conditions such as colon polyps or colon cancer. Functional constipation, on the other hand, is classified into drug-induced constipation, symptomatic constipation, and chronic idiopathic constipation. Drug-induced constipation is caused by drugs that suppress intestinal motility, such as opioids. Symptomatic constipation is constipation that develops secondarily in diseases other than digestive disorders. Chronic idiopathic constipation is the most frequently occurring type of functional constipation. Chronic idiopathic constipation is caused by stress or changes in dietary environment.

[0006] Constipation-predominant irritable bowel syndrome (IBS-C) is a type of constipation characterized by persistent gastrointestinal symptoms, primarily abdominal pain, abdominal discomfort, and bowel irregularities, without any structural changes in the digestive tract. Some patients with functional constipation may also be classified as having IBS-C.

[0007] Drugs used for constipation include osmotic laxatives such as magnesium oxide (saline laxatives) and lactulose (sugar laxatives), bulk-forming laxatives such as polycarbophil calcium, stimulant laxatives such as sennoside and sodium picosulfate, and osmotic laxatives such as dioctyl sodium sulfosuccinate. Serotonin 4 (5-HT4) receptor agonists such as prucalopride and type-2 chloride channel (ClC-2) agonists such as lubiprostone are also used.

[0008] In the drug treatment of constipation, saline laxatives or bulk-forming laxatives are usually used first. Magnesium oxide, a saline laxative, requires caution due to the risk of hypermagnesemia in elderly patients or those with renal impairment. Polycarbophil calcium, a bulk-forming laxative, has a mild effect and takes time to show results. If these drugs are insufficient, stimulant laxatives are used. However, stimulant laxatives act on the enteric nerve plexus and increase peristalsis, but long-term use can lead to addiction, causing atrophy of the nerve plexus and worsening colonic relaxation. Their use should be limited to the smallest possible dose and for the shortest possible duration. Even lubiprostone, which has been approved in recent years, has been shown to cause nausea and vomiting as side effects. Furthermore, it should be administered cautiously to patients with severely impaired renal function.

[0009] Thus, existing constipation medications are still not perfect in terms of safety and efficacy, and patient satisfaction with any of them has been reported to be low (Non-Patent Documents 1 and 2). It is desirable to create safer and more effective constipation medications, as such drugs would be beneficial for many patients with chronic constipation.

[0010] Now, digestive fluids secreted into the digestive tract contain a large amount of sodium. The digestive tract maintains sodium homeostasis in the body by reabsorbing this sodium. In other words, the digestive tract absorbs 9 L of body fluid and approximately 800 mmol of sodium, of which 7.5 L of body fluid and 650 mmol of sodium come from digestive fluids, and the remaining 1.5 L of body fluid and 150 mmol of sodium come from oral sources (Non-Patent Literature 3). The digestive tract absorbs almost all of the sodium, and only about 5 mmol of sodium is excreted in the feces.

[0011] The main mechanisms of sodium reabsorption are electroneuronutral transport and electrogenic transport (Non-Patent Literature 4). Electroneuronutral transport is primarily carried out by NHE3 expressed in the small intestine and proximal colon. For example, it has been reported that about half of sodium absorption in the jejunum is due to NHE3 (Non-Patent Literature 5). Electrogenic transport is carried out in the distal colon by the epithelial sodium channel ENac.

[0012] Substances that inhibit NHE3 activity in the intestinal tract (hereinafter referred to as NHE3 inhibitors) suppress sodium absorption from the intestinal tract, thereby causing sodium to accumulate in the intestinal tract. The accumulated sodium draws out water through osmosis, softening the contents of the intestinal tract. For this reason, NHE3 inhibitors are considered useful as therapeutic agents for chronic constipation, IBS-C, or drug-induced constipation (Non-patent documents 6 and 7).

[0013] Furthermore, NHE3 inhibitors suppress sodium absorption from the intestinal tract, leading to sodium excretion in the feces. Therefore, they are considered useful as drugs that mimic salt reduction.

[0014] Existing antihypertensive drugs such as angiotensin receptor blockers and angiotensin-converting enzyme inhibitors are used to treat hypertension and nephropathy, but their effectiveness is not sufficient. Furthermore, while salt restriction therapy is known to be beneficial in the prevention and treatment of these diseases, it is difficult to continuously adhere to salt restriction in modern life. On the other hand, NHE3 inhibitors that mimic salt restriction have been reported to lower blood pressure in rats, and that when used in combination with angiotensin-converting enzyme inhibitors, they lower blood pressure more strongly (Non-Patent Literature 6). Therefore, NHE3 inhibitors are thought to exert therapeutic effects both as monotherapy and in combination with existing antihypertensive drugs.

[0015] Here, in patients with severe renal failure, excess sodium and fluid cannot be adequately excreted in the urine. Furthermore, the effects of diuretics are lost. Therefore, hemodialysis must be performed several times a week. Between dialysis sessions, weight gain and elevated blood pressure occur due to fluid retention, followed by a decrease in blood pressure as fluid retention improves during dialysis. This repeated cycle of fluid retention and fluid removal during dialysis causes fluctuations in blood pressure, negatively impacting the cardiac function of patients with renal failure, increasing the risk of heart disease and worsening the prognosis. Therefore, to mitigate blood pressure fluctuations, patients with renal failure are required to follow strict salt and fluid restriction between dialysis sessions, but this is difficult to enforce due to its strictness. NHE3 inhibitors have been reported in rats to enhance sodium excretion in the feces, suppress fluid retention, and inhibit cardiac hypertrophy (Non-Patent Literature 7).

[0016] Therefore, NHE3 inhibitors are considered useful as drugs to reduce the risk of developing heart disease in patients with renal failure.

[0017] On the other hand, certain NHE3 inhibitors have been reported to not only suppress sodium absorption from the intestinal tract but also to suppress phosphorus absorption and enhance phosphorus excretion in the feces (Patent Document 1, Non-Patent Document 8). Furthermore, certain NHE3 inhibitors have been reported to lower blood phosphorus levels when administered to rats with renal failure.

[0018] Phosphorus metabolism is maintained by two main actions: absorption and excretion in the small intestine and kidneys. Approximately 1.2 g of phosphorus is ingested per day, of which about 0.4 g, one-third, is excreted in feces, and the remaining about 0.8 g, two-thirds, is absorbed (Non-Patent Document 9). Then, approximately 0.8 g of phosphorus is excreted into urine every day. In addition, phosphorus is also contained in digestive juice and excreted in feces. Within the body, phosphorus is in an equilibrium state between bones and blood.

[0019] Here, in patients with renal failure whose renal function has severely declined, the phosphorus excretion of about 0.8 g per day cannot be achieved, so the blood phosphorus concentration rises, and hyperphosphatemia develops. In hyperphosphatemia, functional abnormalities of bones and parathyroid glands occur, leading to the onset of osteoporosis and hyperparathyroidism. In addition, phosphorus is deposited in blood vessels together with calcium and causes calcification, which increases the onset risk of cardiovascular diseases.

[0020] The guidelines of the Japanese Society for Dialysis Therapy, "Clinical Practice Guidelines for the Management of Bone and Mineral Metabolism Abnormalities Associated with Chronic Kidney Disease", report that mineral metabolism abnormalities occurring in chronic kidney disease not only cause abnormalities in bones and parathyroid glands, but also significantly affect the life prognosis through vascular calcification and the like, and propose these complex diseases as Chronic Kidney Disease-Mineral and Bone Disorder (hereinafter also referred to as CKD-MBD) (Non-Patent Document 10). The CKD-MBD guidelines particularly point out that hyperphosphatemia causes functional abnormalities of bones and parathyroid glands, exacerbates vascular calcification, increases the onset risk of osteoporosis and cardiovascular diseases, and exerts a great influence on life prognosis. It is recommended that hyperphosphatemia be corrected with priority.

[0021] In patients with renal insufficiency, blood phosphorus is removed by dialysis. However, it is not possible to maintain the blood phosphorus concentration within the normal range by dialysis alone. Therefore, as a second-best measure, phosphorus adsorbents, which are therapeutic drugs for hyperphosphatemia, are used. A phosphorus adsorbent is a drug that enhances phosphorus excretion by binding to phosphorus in the intestinal tract and transferring as is to feces. Although these drugs have a definite effect of lowering blood phosphorus concentration, the dose is several grams per day, resulting in a large medication burden. Originally, in dialysis patients who are forced to restrict water intake and have a large number of tablets to take, the medication burden significantly impairs adherence. Phosphorus adsorbents are classified into metal-containing types and polymer-based phosphorus adsorbents, each of which has problems. Metal-based phosphorus adsorbents have concerns about long-term safety due to metal load. In addition, since polymer-based phosphorus adsorbents swell in the intestinal tract, gastrointestinal symptoms such as constipation and abdominal fullness frequently occur.

[0022] Therefore, as a novel therapeutic drug for hyperphosphatemia, a drug with improved safety and convenience and good adherence is desired.

[0023] Since NHE3 inhibitors do not contain metals and are not polymers, they do not have the side effects specific to the above phosphorus adsorbents. It is also considered that the dose can be reduced as compared with phosphorus adsorbents. Therefore, NHE3 inhibitors are considered to be useful as therapeutic agents for hyperphosphatemia with improved safety and convenience and good adherence. And NHE3 inhibitors that can be used for a long period of time are considered to be useful as drugs for improving CKD-MBD.

[0024] In addition, patients with renal insufficiency are imposed water intake restrictions so as not to exacerbate fluid retention. As a result, the water content in the intestinal tract decreases. In addition, patients with renal insufficiency also have a risk of hyperkalemia, and in order to restrict potassium intake, vegetable intake restrictions are imposed. Due to these water intake restrictions and vegetable intake restrictions, patients with renal insufficiency frequently develop constipation. NHE3 inhibitors are considered to have an improving effect even on constipation peculiar to patients with renal insufficiency.

[0025] Thus, NHE3 inhibitors are expected to be extremely useful drugs that can treat hyperphosphatemia and CKD-MBD in patients with renal failure, reduce fluid retention, and even improve constipation in patients with renal failure, thereby comprehensively improving the quality of life (QOL) of patients with renal failure.

[0026] Fluid retention can occur in patients with heart failure, and this fluid retention further exacerbates cardiac function. While diuretics are commonly used to treat heart failure, their effectiveness is reduced in patients with impaired renal function, and they can also cause potassium imbalances. NHE3 inhibitors, however, can excrete fluid in the feces regardless of renal function. Therefore, NHE3 inhibitors are considered a potentially useful novel treatment for heart failure.

[0027] Furthermore, fluid retention can also occur in patients with liver cirrhosis. Drug-induced fluid retention can also occur with PPAR agonists, which are useful in treating type 2 diabetes. NHE3 inhibitors are thought to be able to alleviate these types of fluid retention as well.

[0028] Now, as a compound having NHE3 inhibitory activity, for example, the compound shown in the following formula [1] (1,1'-butane-1,4-diylbis[3-(2-{2-[2-(4-{3-[(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline-4-yl]phenyl}-1H-1,2,3-triazole-1-yl)ethoxy]ethoxy}ethyl)urea]; hereinafter, this may also be referred to as "compound [1]"; also, hereinafter, the compound shown in formula [X] (where X is an integer of 2 or more; a sub-number may also be added) may also simply be referred to as "compound [X]") has been disclosed (see Patent Documents 2 and 3).

[0029]

[0030] Patent documents 2 and 3 disclose a method for producing compound [1] and an intermediate for its production, for example, a production method shown in the following scheme.

[0031]

[0032] In other words, the conventional method for producing compound [1] in the above scheme is characterized by producing and isolating a diazide compound represented by formula [3-d] (hereinafter also referred to as compound [3-d]) from a raw material azidoamine compound represented by formula [3-e] (hereinafter also referred to as compound [3-e]), and then producing compound [1] by a click reaction with an acetylene compound represented by formula [2-h].

[0033] However, in the conventional manufacturing method described above, for example, compound [3-d] is produced using compound [3-e], but (i) it involves handling large quantities of the highly dangerous azidoamine compound [3-e] as a raw material, and (ii) in order to obtain high-purity compound [1], it is necessary to purify and isolate the high-purity diazide compound [3-d] using silica gel column chromatography. Therefore, there were challenges in terms of safety and cost for industrial mass production. In addition, silica gel column chromatography purification was necessary to control the quality of compound [1], and (iii) in the optical resolution of the expensive isoquinoline compound represented by formula [2-a], half the amount of unnecessary enantiomers is discarded. Therefore, there were challenges not only in terms of safety but also in terms of cost, and it could not be said that it was suitable for industrial mass production (Patent Documents 2 and 3). It should be noted that the unnecessary enantiomers generated after the optical resolution of compound [2-a] can be recovered and reused by racemization, but there are no reports on such racemization yet (Non-Patent Documents 11 and 12).

[0034] International Publication No. WO2014 / 169094, International Publication No. WO2016 / 013657, Japanese Patent Publication No. 2017-132759

[0035] Alimentary Pharmacology and Therapeutics, 37, 137-145, 2013. Alimentary Pharmacology and Therapeutics, 25, 599-608, 2007. Annual Review of Physiology, 67, 411-443, 2005. Journal of physiology and pharmacology, 57, 7, 51-79, 2006. American Journal of Physiology-Gastrointestinal and Liver Physiology, 282, G776-G784, 2002. Hypertension, 60, 1560-1567, 2012. Science Translational Medicine, 6, 227ra36, 1-6, 2014. Journal of the American Society of Nephrology, 26, 5, 1138-1149, 2015. Dialysis Next VIII, 2012. Journal of the Japanese Society for Dialysis, 45, 4, 301-356, 2012. Tetrahedron: Asymmetry, 9, 2509-2516, 1998. Organic Process Research & Development. 20, 44-50, 2016.

[0036] The object of the present invention is to solve the aforementioned safety and cost issues and provide a method for producing a compound represented by formula [1] (1,1'-butane-1,4-diylbis[3-(2-{2-[2-(4-{3-[(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline-4-yl]phenyl}-1H-1,2,3-triazole-1-yl)ethoxy]ethoxy}ethyl)urea] or a pharmaceutically acceptable salt thereof or a solvate thereof that has excellent physiological activity and is suitable for industrial mass production.

[0037] As a result of studies conducted to solve the above problems, the present inventors have solved the safety and cost issues by using compound [3-a] as a raw material to avoid the use of the highly dangerous azidoamine compound [3-e], and by converting compound [3-a] to compound [3-b], halogenating compound [3-b] to produce a high-purity dihalogen compound [3-c], and then azidating compound [3-c] to produce the diazide compound [3-d], as shown in the scheme below.

[0038] (In the scheme, Acid indicates an acid that forms a salt with an amine. X indicates a halogen atom.)

[0039] In addition, the inventors were able to avoid isolation and purification using silica gel column chromatography by producing compound [2-d] as a salt, thereby improving cost-related issues. Furthermore, the inventors discovered conditions for isomerization by subjecting the expensive isoquinoline compound represented by formula [2-b] or [2-c] to basic conditions. This made it possible to racemize the unwanted enantiomer (compound [2-c]) obtained after optical resolution, and to reuse compound [2-a] obtained by this racemization in optical resolution, dramatically improving cost-related issues.

[0040] By combining the above methods, we found a method for producing a compound [1] suitable for industrial mass production that improves safety and cost.

[0041] In other words, the present invention is as follows: <1> One aspect of the present invention is a method comprising the steps of producing compound [2-e] and compound [3-d], wherein the obtained compound [2-e] and compound [3-d] are reacted to produce a compound represented by formula [1], a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein the step of producing compound [2-e] includes the step of reacting compound [2-c] with a base to perform racemization and produce compound [2-a].

[0042] (In the formula, Acid indicates an acid that forms a salt with an amine.)

[0043]

[0044]

[0045] The objective is to provide the following. <2> One aspect of the present invention is a method for producing a compound represented by formula [1], comprising the steps of producing compound [2-e] and compound [3-d], wherein the step of producing compound [2-e] includes the step of reacting compound [2-c] with a base to perform racemization and produce compound [2-a].

[0046] (In the formula, Acid indicates an acid that forms a salt with an amine.)

[0047]

[0048]

[0049] The objective is to provide.

[0050] <3> One aspect of the present invention is a manufacturing method according to <1> or <2> above, wherein the step of producing compound [2-e] includes a step of performing optical resolution on the obtained compound [2-a] to produce compound [2-b].

[0051] The objective is to provide.

[0052] <4> One aspect of the present invention is the manufacturing method described in <3> above, wherein the step of producing compound [2-e] includes a step of converting the obtained compound [2-b] into compound [2-d].

[0053] The objective is to provide (in the scheme, Acid has the same meaning as above).

[0054] <5> One aspect of the present invention is the manufacturing method described in <4> above, wherein the step of producing compound [2-e] includes a step of converting the obtained compound [2-d] into compound [2-e].

[0055] The objective is to provide (in the scheme, Acid has the same meaning as above).

[0056] <6> One aspect of the present invention is the manufacturing method according to <1> or <2> above, wherein the step of producing compound [3-d] includes a step of reacting compound [3-c] with an azidation reagent to produce compound [3-d].

[0057] The objective is to provide (where X represents a halogen atom in the scheme).

[0058] <7> One aspect of the present invention is the manufacturing method described in <6> above, wherein the step of producing compound [3-d] includes a step of reacting compound [3-b] with a halogenating reagent to convert it to compound [3-c].

[0059] The objective is to provide (where X has the same meaning as above).

[0060] <8> One aspect of the present invention is the manufacturing method described in <7> above, wherein the step of producing compound [3-d] includes a step of converting compound [3-a] to compound [3-b].

[0061] The objective is to provide.

[0062] <9> One aspect of the present invention is a compound represented by formula [2-d'] which is a tartrate or a solvate thereof.

[0063] The objective is to provide.

[0064] <10> One aspect of the present invention is a compound represented by formula [3-b] or a salt thereof, or a solvate thereof

[0065] The objective is to provide.

[0066] <11> One aspect of the present invention is a compound represented by formula [3-c] or a salt thereof, or a solvate thereof

[0067] (In the formula, X has the same meaning as above.) To provide <12> One aspect of the present invention is to provide a method for producing the compound represented by formula [1] or a pharmaceutically acceptable salt thereof or a solvate thereof is a tartrate salt of the compound represented by formula [1]. <13> One aspect of the present invention is to provide a method for producing the compound represented by formula [1] or a pharmaceutically acceptable salt thereof or a solvate thereof is a (L)-(+)-tartrate salt of the compound represented by formula [1].

[0068] <14> One aspect of the present invention is a method for producing compound [3-d], comprising the step of reacting compound [3-c] with an azidation reagent to produce compound [3-d].

[0069] The objective is to provide (where X represents a halogen atom in the scheme).

[0070] <15> One aspect of the present invention is the manufacturing method described in <14> above, further comprising the step of reacting compound [3-b] with a halogenating reagent to convert it to compound [3-c].

[0071] The objective is to provide (where X has the same meaning as above).

[0072] <16> One aspect of the present invention is the manufacturing method described in <15>, further comprising the step of converting compound [3-a] to compound [3-b].

[0073] The objective is to provide.

[0074] <17> One aspect of the present invention is a method for producing a compound represented by formula [A] or a pharmaceutically acceptable salt thereof or a solvate thereof from compound [2-b], wherein the step of producing compound [2-b] includes the steps of reacting compound [2-c] with a base to perform racemization to produce compound [2-a], and performing optical resolution on the obtained compound [2-a] to produce compound [2-b].

[0075]

[0076]

[0077] The objective is to provide the following: <18> One aspect of the present invention is a method for producing a compound represented by formula [A] from compound [2-b], wherein the step of producing compound [2-b] includes the steps of reacting compound [2-c] with a base to perform racemization to produce compound [2-a], and performing optical resolution on the obtained compound [2-a] to produce compound [2-b].

[0078]

[0079]

[0080] The objective is to provide.

[0081] <19> One aspect of the present invention is a crystal of compound [1] having an endothermic peak at 103°C to 123°C, measured in a differential scanning calorimeter (DSC).

[0082] The objective is to provide.

[0083] <20> One aspect of the present invention provides a method for producing crystals of compound [1] having an endothermic peak of 103°C to 123°C in a differential scanning calorimeter (DSC), the method comprising the steps of dissolving compound [1] in a mixed solvent of ethanol and acetonitrile, heating it, adding acetonitrile, cooling it, and crystallizing it at room temperature.

[0084] <21> One aspect of the present invention is to provide a combination pharmaceutical product of compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof and a therapeutic agent for CKD-MBD.

[0085] <22> One aspect of the present invention is to provide a pharmaceutical composition comprising compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof and a therapeutic agent for CKD-MBD.

[0086] <23> One aspect of the present invention is to provide a combination pharmaceutical of compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof and a phosphate binder, wherein the phosphate binder is one or more selected from the group consisting of calcium carbonate, sevelamer, bixalomer, lanthanum carbonate and ferric citrate.

[0087] <24> One aspect of the present invention is to provide a pharmaceutical composition comprising compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof and a phosphate binder, wherein the phosphate binder is one or more selected from the group consisting of calcium carbonate, sevelamer, bixalomer, lanthanum carbonate and ferric citrate.

[0088] <25> One aspect of the present invention is to provide a combination pharmaceutical product of compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof with sevelamer.

[0089] <26> One aspect of the present invention is to provide a pharmaceutical composition comprising compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof and a sevelamer.

[0090] The present invention enables the efficient industrial mass production of compound [1], its pharmaceutically acceptable salts, or solvates thereof.

[0091] This diagram shows the combined effects of compound [1] and sevelamer hydrochloride in a hyperphosphatemia model rat. This diagram shows the combined effects of compound [1] and lanthanum carbonate in a hyperphosphatemia model rat. This diagram shows the combined effects of compound [1] and ferric citrate in a hyperphosphatemia model rat. This diagram shows the combined effects of compound [1] and calcium carbonate in a hyperphosphatemia model rat.

[0092] In this specification, the terms have the following meanings: "Halogen atom" refers to a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom. "Acid" refers to acids that form salts with amines, such as hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid, methanesulfonic acid, tartaric acid, fumaric acid, maleic acid, and dibenzoyl tartaric acid, but is not limited to these.

[0093] Regarding "good solvents," good solvents for the free form of compound [1] include, for example, alcohol-based solvents such as methanol, ethanol, and 2-propanol; ether-based solvents such as tetrahydrofuran and 2-methyltetrahydrofuran; amide-based solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; dimethyl sulfoxide; or mixed solvents thereof. In addition, although the free form of compound [1] does not dissolve in water alone, a mixed solvent of water and a solvent that is miscible with water can also be used as a good solvent. Furthermore, good solvents for the tartrate salt of compound [1] include, for example, alcohol-based solvents such as methanol, ethanol, and 2-propanol; ketone-based solvents such as acetone; ether-based solvents such as tetrahydrofuran and 2-methyltetrahydrofuran; amide-based solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; dimethyl sulfoxide; water; or mixed solvents thereof. Regarding "poor solvents," examples of poor solvents for the free form of compound [1] include ketone solvents such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; hydrocarbon solvents such as heptane, toluene, and xylene; ester solvents such as ethyl acetate and isopropyl acetate; nitrile solvents such as acetonitrile and propanenitrile; and water. Furthermore, examples of poor solvents for the tartrate salt of compound [1] include hydrocarbon solvents such as heptane, toluene, and xylene; ester solvents such as ethyl acetate and isopropyl acetate; and nitrile solvents such as acetonitrile and propanenitrile.

[0094] "Room temperature" refers to 1-30°C unless otherwise specified. "Ice-cooled" and "ice-cooled temperature" refer to 0-5°C unless otherwise specified.

[0095] The present invention relates to a method for producing compound [1] or its pharmaceutically acceptable salts or solvates thereof. The present invention also relates to compounds [2-d], [2-e], [3-b], [3-c], and [3-d], which are intermediates in the production thereof. Furthermore, the present invention relates to a method for producing compound [2-a] by racemizing the optically active compound [2-c]. The present invention can be carried out according to the following scheme.

[0096] (In the scheme, X and Acid have the same meanings as above.) Step 1-1:

[0097] In a preferred embodiment of the present invention, compounds [2-b] and [2-c] can be obtained by reacting compound [2-a] with a chiral carboxylic acid that acts as an optical resolution agent in a solvent to form a salt. Examples of usable solvents include alcoholic solvents such as methanol, ethanol, and 2-propanol; ketone solvents such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; hydrocarbon solvents such as heptane, toluene, and xylene; halogenated solvents such as chloroform, 1,2-dichloroethane, and chlorobenzene; ester solvents such as ethyl acetate and isopropyl acetate; ether solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; amide solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; nitrile solvents such as acetonitrile and propanenitrile; dimethyl sulfoxide; water; or mixed solvents thereof. Preferably, the solvent is an alcohol-based solvent such as methanol, ethanol, or 2-propanol; water; or a mixture thereof. Examples of chiral carboxylic acids that can be preferably used in the present invention include compounds having chirality at the α-position of the carboxylic acid, such as dibenzoyl-L-tartaric acid, dibenzoyl-D-tartaric acid, L-tartaric acid, D-tartaric acid, (R)-(-)-2-phenylpropionic acid, (S)-(+)-2-phenylpropionic acid, L-(+)-mandelic acid, and D-(-)-mandelic acid. In optical resolution, the mixture may be heated to dissolve enantiomers or impurities that are not in the desired absolute configuration for purification by recrystallization, reslurrying, or crystallization. The heating temperature is usually from 30°C to the boiling point of the solvent used, preferably 30 to 100°C, and more preferably 40 to 80°C. In some cases, heating may not be necessary. Furthermore, the filtration temperature of the precipitate is usually from -20°C to the boiling point of the solvent used, preferably -20 to 40°C, and more preferably -10 to 25°C.In the present invention, the amount of chiral carboxylic acid used is preferably 0.4 to 10 molar equivalents, more preferably 0.4 to 1.5 molar equivalents, and even more preferably 0.4 to 1.0 molar equivalent, relative to the starting compound [2-a]. The amount of solvent used is preferably 1 to 100 times the mass of the starting compound [2-a], more preferably 1 to 50 times the mass, and even more preferably 1 to 30 times the mass. Compound [2-b] or compound [2-c] can be obtained as a purified or unpurified product by methods such as recrystallization, reslurrying, or crystallization. Alternatively, the enantiomer compound [2-c] or [2-b] can be obtained by crystallization from the filtrate obtained by filtering out compound [2-b] or [2-c]. Step 1-2:

[0098] Compound [2-a] can be obtained by racemizing compound [2-c] in a solvent by reacting it with a base. While compound [2-c] is usually in its free form, it can also be used in which a salt has been formed with a suitable acid. Suitable solvents include, for example, alcoholic solvents such as methanol, ethanol, and 2-propanol; hydrocarbon solvents such as heptane, toluene, and xylene; halogenated solvents such as chloroform, 1,2-dichloroethane, and chlorobenzene; ester solvents such as ethyl acetate and isopropyl acetate; ether solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; amide solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; nitrile solvents such as acetonitrile and propanenitrile; dimethyl sulfoxide; water; or mixtures thereof. Preferably, the solvents are alcoholic solvents such as methanol, ethanol, and 2-propanol; hydrocarbon solvents such as heptane, toluene, and xylene; etheric solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; water; or mixed solvents thereof. Suitable bases include inorganic bases such as sodium hydroxide and lithium hydroxide; or organic bases such as sodium methoxide, potassium ethoxide, sodium bis(trimethylsilyl)amide, and lithium bis(trimethylsilyl)amide. The reaction temperature is usually from -20°C to the boiling point of the solvent used, preferably 50 to 140°C, and more preferably 60 to 120°C. The amount of base used is preferably 1 to 100 molar equivalents, more preferably 1.5 to 30 molar equivalents, and even more preferably 2 to 15 molar equivalents relative to the starting compound [2-c].The amount of solvent used is preferably 1 to 100 times the mass of the raw material compound [2-c], more preferably 1 to 50 times the mass, and even more preferably 1 to 30 times the mass. Compound [2-a] can be obtained as a purified or unpurified product by methods such as recrystallization, reslurrying, or crystallization. Step 2:

[0099] (In the scheme, Acid has the same meaning as above.) In a preferred embodiment of the present invention, compound [2-g] can be obtained by reacting compound [2-b] with trimethylsilylacetylene, a base, a copper catalyst, and a palladium catalyst in a solvent, followed by post-treatment, and then adding an acid to form a salt compound [2-d].

[0100] (1) Examples of solvents used when producing compound [2-g] from compound [2-b] include alcoholic solvents such as methanol, ethanol, and 2-propanol; ketone solvents such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; hydrocarbon solvents such as heptane, toluene, and xylene; halogenated solvents such as chloroform, 1,2-dichloroethane, and chlorobenzene; ester solvents such as ethyl acetate and isopropyl acetate; ether solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; amide solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; nitrile solvents such as acetonitrile and propanenitrile; dimethyl sulfoxide; water; or mixed solvents thereof. Organic bases such as triethylamine, diisopropylamine, and pyridine can also be used as solvents in the production process. Preferred solvents include hydrocarbon solvents such as heptane, toluene, and xylene; ether solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; or mixed solvents thereof; and organic bases such as triethylamine, diisopropylamine, and pyridine. Examples of bases that can be preferably used in the present invention include triethylamine, diisopropylamine, and pyridine. Examples of copper catalysts that can be preferably used in the present invention include copper(I) iodide, copper(I) bromide, and copper(II) acetate. Examples of palladium catalysts that can be preferably used in the present invention include palladium chloride, palladium acetate, bis(triphenylphosphine)palladium dichloride, and tetrakis(triphenylphosphine)palladium. If necessary, phosphine ligands such as triphenylphosphine and tris(2-methylphenyl)phosphine may be added together with the above catalysts.The reaction temperature is usually from -20°C to the boiling point of the solvent used, preferably 20 to 100°C, and more preferably 50 to 100°C. The amount of trimethylsilylacetylene used is preferably 0.5 to 10 molar equivalents, more preferably 0.8 to 5 molar equivalents, and even more preferably 1 to 2 molar equivalents, relative to the starting compound [2-b]. The amount of base used is preferably 1 to 100 molar equivalents, more preferably 1 to 50 molar equivalents, and even more preferably 1 to 20 molar equivalents, relative to the starting compound [2-b]. The amount of copper catalyst used is preferably 0.001 to 1 molar equivalent, more preferably 0.005 to 0.5 molar equivalents, and even more preferably 0.01 to 0.4 molar equivalents, relative to the starting compound [2-b]. The amount of palladium catalyst used is preferably 0.001 to 1 molar equivalent, more preferably 0.005 to 0.5 molar equivalents, and even more preferably 0.01 to 0.4 molar equivalents, relative to the raw material compound [2-b]. The amount of solvent used is preferably 1 to 100 times the mass of the raw material compound [2-b], more preferably 1 to 30 times the mass, and even more preferably 1 to 10 times the mass.

[0101] (2) When forming a salt with compound [2-g] to produce compound [2-d], examples of solvents include alcohol-based solvents such as methanol, ethanol, and 2-propanol; ketone-based solvents such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; hydrocarbon-based solvents such as heptane, toluene, and xylene; halogen-based solvents such as chloroform, 1,2-dichloroethane, and chlorobenzene; ester-based solvents such as ethyl acetate and isopropyl acetate; ether-based solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; amide-based solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; nitrile-based solvents such as acetonitrile and propanenitrile; dimethyl sulfoxide; water; or mixed solvents thereof. Preferably, alcohol-based solvents such as methanol, ethanol, and 2-propanol; water; or mixed solvents thereof. Suitable acids include hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid, methanesulfonic acid, tartaric acid, fumaric acid, maleic acid, and dibenzoyl tartaric acid. During crystallization, the heating temperature is from 30°C to the boiling point of the solvent used, preferably 30 to 100°C, and more preferably 30 to 50°C. In some cases, heating may not be necessary. The filtration temperature of the precipitate is usually from -20°C to the boiling point of the solvent used, preferably -20 to 40°C, and more preferably -10 to 10°C. The amount of acid used is preferably 0.5 to 5 molar equivalents, more preferably 1 to 3 molar equivalents, and even more preferably 1 to 1.5 molar equivalents relative to the raw material compound [2-b]. The amount of solvent used is preferably 1 to 100 times the mass of the raw material compound [2-b], more preferably 1 to 50 times the mass, and even more preferably 1 to 30 times the mass. Compound [2-d] can be obtained as a purified product or an unpurified product by methods such as recrystallization, reslurrying, or crystallization. Step 3:

[0102] (In the scheme, Acid has the same meaning as above.) In a preferred embodiment of the present invention, compound [2-h] can be obtained by reacting compound [2-d] with a base in a solvent. Furthermore, in a preferred embodiment of the present invention, compound [2-e] can be obtained by adding an acid to the obtained compound [2-h] in a solvent.

[0103] (1) Examples of solvents used when producing compound [2-h] from compound [2-d] include alcohol-based solvents such as methanol, ethanol, and 2-propanol; ketone-based solvents such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; hydrocarbon-based solvents such as heptane, toluene, and xylene; halogen-based solvents such as chloroform, 1,2-dichloroethane, and chlorobenzene; ester-based solvents such as ethyl acetate and isopropyl acetate; ether-based solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; amide-based solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; nitrile-based solvents such as acetonitrile and propanenitrile; dimethyl sulfoxide; water; or mixed solvents thereof. Preferably, the solvents are alcohol-based solvents such as methanol, ethanol, and 2-propanol; ether-based solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; water; or mixed solvents thereof. Examples of bases that can be preferably used in the present invention include sodium bicarbonate, potassium carbonate, and sodium hydroxide. The reaction temperature is usually from -20°C to the boiling point of the solvent used, preferably 0 to 100°C, and more preferably 10 to 30°C. The amount of base used is preferably 1 to 10 molar equivalents, more preferably 1.5 to 5 molar equivalents, and even more preferably 2 to 5 molar equivalents relative to the starting compound [2-d]. The amount of solvent used is preferably 1 to 100 times the mass of the starting compound [2-d], more preferably 1 to 50 times the mass, and even more preferably 1 to 30 times the mass.

[0104] (2) Examples of solvents used to produce compound [2-e] from compound [2-h] include alcoholic solvents such as methanol, ethanol, and 2-propanol; ketone solvents such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; hydrocarbon solvents such as heptane, toluene, and xylene; halogenated solvents such as chloroform, 1,2-dichloroethane, and chlorobenzene; ester solvents such as ethyl acetate and isopropyl acetate; ether solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; amide solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; nitrile solvents such as acetonitrile and propanenitrile; dimethyl sulfoxide; water; or mixed solvents thereof. Preferably, the solvents are alcohol-based solvents such as methanol, ethanol, and 2-propanol; ether-based solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; or mixed solvents thereof. Suitable acids include hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid, methanesulfonic acid, tartaric acid, fumaric acid, maleic acid, and dibenzoyl tartaric acid. During crystallization, the heating temperature is usually from 30°C to the boiling point of the solvent used, preferably 30 to 100°C, and more preferably 40 to 70°C. In some cases, heating may not be necessary. The filtration temperature of the precipitate is usually from -20°C to the boiling point of the solvent used, preferably -15 to 40°C, and more preferably -10 to 10°C. The amount of acid used is preferably 0.5 to 5 molar equivalents, more preferably 1 to 3 molar equivalents, and even more preferably 1 to 1.5 molar equivalents, relative to the raw material compound [2-d].The amount of solvent used is preferably 1 to 100 times the mass of the raw material compound [2-d], more preferably 1 to 50 times the mass, and even more preferably 1 to 30 times the mass. Compound [2-e] can be obtained as a purified product or an unpurified product by methods such as recrystallization, reslurrying, or crystallization. Step 4:

[0105] In a preferred embodiment of the present invention, compound [3-b] can be obtained by reacting compound [3-a] with 1,4-diisocyanatobutane in a solvent. Examples of usable solvents include alcoholic solvents such as methanol, ethanol, and 2-propanol; ketone solvents such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; hydrocarbon solvents such as heptane, toluene, and xylene; halogenated solvents such as chloroform, 1,2-dichloroethane, and chlorobenzene; ester solvents such as ethyl acetate and isopropyl acetate; ether solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; amide solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; nitrile solvents such as acetonitrile and propanenitrile; dimethyl sulfoxide; water; or mixed solvents thereof. Preferably, the solvents are alcohol-based solvents such as methanol, ethanol, and 2-propanol; ketone-based solvents such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; hydrocarbon-based solvents such as heptane, toluene, and xylene; ester-based solvents such as ethyl acetate and isopropyl acetate; ether-based solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; nitrile-based solvents such as acetonitrile and propanenitrile; water; or a mixture thereof. The reaction temperature is usually from -20°C to the boiling point of the solvent used, preferably -15 to 60°C, and more preferably -10 to 10°C. The amount of compound [3-a] used is preferably 1 to 10 molar equivalents, more preferably 1.5 to 5 molar equivalents, and even more preferably 2 to 3 molar equivalents relative to 1,4-diisocyanatobutane. The amount of solvent used is preferably 1 to 300 times the mass of the raw material 1,4-diisocyanatobutane, more preferably 1 to 100 times the mass, and even more preferably 10 to 50 times the mass.Compound [3-b] can be obtained as a purified or unpurified product by methods such as recrystallization, reslurrying, or crystallization. Step 5:

[0106] (In the scheme, X has the same meaning as above.) In a preferred embodiment of the present invention, compound [3-c] can be obtained by reacting compound [3-b] with a halogenating agent (halogenating reagent) and a phosphine compound in a solvent. Examples of usable solvents include ketone solvents such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; hydrocarbon solvents such as heptane, toluene, and xylene; halogen solvents such as chloroform, 1,2-dichloroethane, and chlorobenzene; ester solvents such as ethyl acetate and isopropyl acetate; ether solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; amide solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; nitrile solvents such as acetonitrile and propanenitrile; dimethyl sulfoxide; water; or mixed solvents thereof. Preferably, the solvents are hydrocarbon solvents such as heptane, toluene, and xylene; halogenated solvents such as chloroform, 1,2-dichloroethane, and chlorobenzene; ether solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; nitrile solvents such as acetonitrile and propanenitrile; water; or mixed solvents thereof. Suitable halogenating agents include, for example, N-chlorosuccinimide (NCS), carbon tetrachloride, N-bromosuccinimide (NBS), carbon tetrabromide, bromine, N-iodosuccinimide (NIS), and iodine. Suitable phosphine compounds for use in the present invention include, for example, triphenylphosphine and tributylphosphine. The reaction temperature is usually from -20°C to the boiling point of the solvent used, preferably -15 to 60°C, and more preferably -10 to 30°C.The amount of halogenating agent used is preferably 1 to 10 molar equivalents, more preferably 1.5 to 5 molar equivalents, and even more preferably 2 to 3 molar equivalents, relative to the raw material compound [3-b]. The amount of phosphine compound used is preferably 1 to 10 molar equivalents, more preferably 1.5 to 5 molar equivalents, and even more preferably 2 to 3 molar equivalents, relative to the raw material compound [3-b]. The amount of solvent used is preferably 1 to 300 times the mass of the raw material compound [3-b], more preferably 1 to 100 times the mass, and even more preferably 10 to 50 times the mass. Compound [3-c] can be obtained as a purified product or an unpurified product by methods such as recrystallization, reslurrying, or crystallization. Step 6:

[0107] (In the scheme, X has the same meaning as above.) Compound [3-d] can be obtained by reacting compound [3-c] with an azidating agent (azidating reagent) in a solvent. Examples of usable solvents include alcoholic solvents such as methanol, ethanol, and 2-propanol; ketone solvents such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; hydrocarbon solvents such as heptane, toluene, and xylene; halogenated solvents such as chloroform, 1,2-dichloroethane, and chlorobenzene; ester solvents such as ethyl acetate and isopropyl acetate; ether solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; amide solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; nitrile solvents such as acetonitrile and propanenitrile; dimethyl sulfoxide; water; or mixed solvents thereof. Preferably, the solvents are ether-based solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butylmethyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, diethoxymethane; amide-based solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, N-methyl-2-pyrrolidone; water; or a mixture thereof. Suitable azidating agents include, for example, sodium azide, tetrabutylammonium azide, and diphenyl phosphate azide. If necessary, bases such as triethylamine, N,N-diisopropylethylamine, and sodium bicarbonate may be added together with the azidating agent. The reaction temperature is usually from -20°C to the boiling point of the solvent used, preferably 20 to 100°C, and more preferably 40 to 80°C. The amount of azidating agent used is preferably 1 to 10 molar equivalents, more preferably 1.5 to 5 molar equivalents, and even more preferably 2 to 3 molar equivalents, relative to the raw material compound [3-c].The amount of solvent used is preferably 1 to 100 times the mass of the raw material compound [3-c], more preferably 1 to 50 times the mass, and even more preferably 1 to 30 times the mass. Compound [3-d] can be obtained as a purified or unpurified product by methods such as recrystallization, reslurrying, or crystallization. Alternatively, compound [3-d] can be used in the next step as a solution without isolation or purification. Step 7:

[0108] (In the scheme, Acid has the same meaning as above.) In a preferred embodiment of the present invention, compound [1] can be obtained by reacting compound [2-e] obtained in step 3 and compound [3-d] obtained in step 6 with a base and a copper catalyst in a solvent. Examples of usable solvents include alcohol-based solvents such as methanol, ethanol, and 2-propanol; ketone-based solvents such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; hydrocarbon-based solvents such as heptane, toluene, and xylene; halogen-based solvents such as chloroform, 1,2-dichloroethane, and chlorobenzene; ester-based solvents such as ethyl acetate and isopropyl acetate; ether-based solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; amide-based solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; nitrile-based solvents such as acetonitrile and propanenitrile; dimethyl sulfoxide; water; or mixtures thereof. Preferably, the solvents are alcoholic solvents such as methanol, ethanol, and 2-propanol; esteric solvents such as ethyl acetate and isopropyl acetate; etheric solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; amide solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; water; or mixtures thereof. Preferred bases for use in the present invention include inorganic bases such as sodium bicarbonate, potassium carbonate, and sodium hydroxide; organic bases such as triethylamine, diisopropylamine, and pyridine; or mixtures thereof. Preferred copper catalysts for use in the present invention include, for example, copper(I) iodide, copper(II) iodide, copper(I) bromide, copper(II) bromide, and copper(II) acetate. If necessary, reducing agents such as ascorbic acid, triphenylphosphine, and iron may be added together with the catalyst.The reaction temperature is usually from -20°C to the boiling point of the solvent used, preferably -15 to 100°C, and more preferably 10 to 50°C. The amount of compound [2-e] used is preferably 1 to 10 molar equivalents, more preferably 1.5 to 5 molar equivalents, and even more preferably 1.5 to 2.5 molar equivalents, relative to the starting compound [3-d]. The amount of base used is preferably 1 to 10 molar equivalents, more preferably 1.5 to 5 molar equivalents, and even more preferably 2 to 3 molar equivalents, relative to the starting compound [3-d]. The amount of copper catalyst used is preferably 0.001 to 1 molar equivalent, more preferably 0.005 to 0.5 molar equivalents, and even more preferably 0.01 to 0.4 molar equivalents, relative to the starting compound [3-d]. The amount of solvent used is preferably 1 to 100 times the mass of the starting compound [3-d], more preferably 1 to 50 times the mass, and even more preferably 1 to 30 times the mass. Compound [1] can be obtained as a purified or unpurified product by methods such as recrystallization, reslurrying, or crystallization.

[0109] Furthermore, the obtained compound [1] can be converted by conventional methods to its solvate, or to various pharmaceutically acceptable salts or their solvates. The converted solvates or salts can also be converted by conventional methods to crystalline or amorphous forms.

[0110] Here, "pharmaceutically acceptable salts" include, for example, mineral salts such as hydrochloride, hydrobromide, hydroiodide, phosphate, sulfate, and nitrate; sulfonates such as methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and trifluoromethanesulfonate; organic salts such as oxalate, tartrate, citrate, maleate, succinate, acetate, trifluoroacetate, benzoate, mandelate, ascorbate, lactate, gluconate, and malate; amino acid salts such as glycine salt, lysine salt, arginine salt, ornithine salt, glutamate, and aspartate; or inorganic salts such as lithium salt, sodium salt, potassium salt, calcium salt, and magnesium salt, or ammonium salts; and salts with organic bases such as triethylamine salt, diisopropylamine salt, and cyclohexylamine salt. Note that hydrated salts are included in the definition of salt.

[0111] Furthermore, "solvates" are solvates that are pharmaceutically acceptable. Examples include hydrates, ethanol hydrates, and lower alcohol hydrates such as 2-propanol hydrate.

[0112] Furthermore, in the manufacture of compound [1] or its pharmaceutically acceptable salts or solvates thereof, the salts and solvates relating to the intermediates in the manufacture are not limited to those pharmaceutically acceptable as described above.

[0113] The free form of compound [1] and its production method are described below.

[0114] The free crystal of compound [1] has the following properties: (a) In differential scanning calorimeter (DSC), the endothermic peak is between 103°C and 123°C.

[0115] Note that characteristic peaks obtained by differential scanning calorimeter (DSC) may vary depending on the measurement conditions. Therefore, errors may occur or these peaks may not be clear in the crystals of the free form of compound [1].

[0116] As shown in the examples described later, crystals of the free form of compound [1] can be reproducibly obtained as single crystals of consistent quality, and can be stably supplied as active pharmaceutical ingredient crystals used in the manufacture of pharmaceuticals and pharmaceutical raw materials, possessing excellent physicochemical properties and storage stability.

[0117] Next, the free form crystals of compound [1] can be produced, for example, by the following method.

[0118] The free form of compound [1] is dissolved in a predetermined good solvent (first solvent), and if necessary, heated, to dissolve it. Then, crystals are precipitated by slow cooling or by adding a predetermined poor solvent (second solvent). After separating the precipitated crystals from the solvent by filtering, centrifugation, etc., the free form of compound [1] can be obtained by drying as necessary. Crystallization may be repeated not only once but two or more times, but usually only once is performed. Here, crystallization can be carried out using only the good solvent (first solvent), or it can be carried out using a mixed solvent of the good solvent (first solvent) and the poor solvent (second solvent).

[0119] The cooling time is not particularly limited as long as it is 10 seconds or longer, but it is usually between 10 minutes and 24 hours, and preferably between 30 minutes and 5 hours.

[0120] Furthermore, seed crystals can be used during crystallization. Seed crystals can be obtained by methods well known to those skilled in the art, such as scraping the wall of a container holding the crystallization solution with a spatula, or by performing a solvent evaporation method in which the compound solution is concentrated by slowly evaporating the solvent to obtain crystals.

[0121] The crystallization of the free form of compound [1] is described in detail below.

[0122] The triazole reaction in step 7 is post-processed to obtain compound [1]. The free form of the obtained compound [1] is dissolved in a mixed solvent of ethanol and acetonitrile, heated, and then acetonitrile is added, followed by cooling and crystallization at room temperature. In the crystallization of the free form of compound [1], the heating temperature is usually from room temperature to the boiling point of the solvent used, preferably from room temperature to 100°C, and more preferably from 40 to 70°C. In some cases, heating may not be necessary. The filtration temperature of the precipitate is usually from -20°C to the boiling point of the solvent used, preferably from -15 to 40°C, more preferably from -10°C to room temperature, and even more preferably from room temperature. The amount of solvent used is preferably 1 to 100 times the mass of the free form of the raw material compound [1], more preferably from 1 to 50 times the mass, and even more preferably from 1 to 30 times the mass.

[0123] The conversion of compound [1] to its tartrate salt is described below.

[0124] The tartrate salt of compound [1] (hereinafter sometimes referred to as compound [1']) can be obtained, for example, by the method shown below.

[0125] (1) Compound [1'] can be obtained by dissolving compound [1] and (L)-tartaric acid in a good solvent and adding the resulting solution dropwise to a poor solvent. Examples of good solvents that can be used include alcoholic solvents such as methanol, ethanol, and 2-propanol; ketoneic solvents such as acetone; etheric solvents such as tetrahydrofuran and 2-methyltetrahydrofuran; amideic solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; dimethyl sulfoxide; water; or mixed solvents thereof. Preferably, alcoholic solvents such as methanol, ethanol, and 2-propanol; etheric solvents such as tetrahydrofuran and 2-methyltetrahydrofuran; or mixed solvents thereof. Examples of poor solvents that can be used include hydrocarbon solvents such as heptane, toluene, and xylene; esteric solvents such as ethyl acetate and isopropyl acetate; nitrile solvents such as acetonitrile and propanenitrile; or mixed solvents thereof. Preferably, esteric solvents such as ethyl acetate and isopropyl acetate; nitrile solvents such as acetonitrile and propanenitrile; or mixed solvents thereof. The temperature during dropwise addition to the poor solvent and crystallization is usually from -20°C to the boiling point of the solvent used, preferably -15 to 60°C, and more preferably -10 to 10°C. The amount of (L)-tartaric acid used is preferably 0.5 to 5 molar equivalents, more preferably 1 to 3 molar equivalents, and even more preferably 1 to 2.5 molar equivalents relative to compound [1]. The amount of solvent used is preferably 1 to 500 times the mass of compound [1], more preferably 100 to 400 times the mass, and even more preferably 200 to 300 times the mass.

[0126] (2) Compound [1'] can also be obtained by dissolving compound [1] and (L)-tartaric acid in a solvent and drying the solution by spraying it with a spray dryer, adjusting the spray drying parameters as needed. Examples of solvents that can be used include alcoholic solvents such as methanol, ethanol, and 2-propanol; ketone solvents such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; hydrocarbon solvents such as heptane, toluene, and xylene; halogenated solvents such as chloroform, 1,2-dichloroethane, and chlorobenzene; ester solvents such as ethyl acetate and isopropyl acetate; ether solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, tetrahydropyran, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and diethoxymethane; amide solvents such as N,N-dimethylformamide, N,N-dimethylacetoxyamide, and N-methyl-2-pyrrolidone; nitrile solvents such as acetonitrile and propanenitrile; dimethyl sulfoxide; water; or mixed solvents thereof. Preferably, the solvent is an alcohol-based solvent such as methanol, ethanol, or 2-propanol; water; or a mixture thereof. The amount of (L)-tartaric acid used is preferably 0.5 to 5 molar equivalents, more preferably 1 to 3 molar equivalents, and even more preferably 1 to 2.5 molar equivalents, relative to compound [1].

[0127] Furthermore, compound [1] can be converted by conventional methods, for example, to its hydrochloride salt (hereinafter sometimes referred to as compound [1'').

[0128]

[0129] Compound [1] produced by the present invention has NHE3 inhibitory activity. Compound [1] can relieve constipation by softening the intestinal contents by causing sodium to accumulate in the intestinal tract and drawing out water. Here, constipation includes organic constipation, drug-induced constipation, symptomatic constipation, and other types of constipation.

[0130] Compound [1] can also be used in combination with existing or under-development laxatives that have mechanisms of action other than NHE3 inhibition. By combining compound [1] with other drugs, a stronger pharmacological effect can be expected compared to the effect obtained by each drug alone.

[0131] Examples of existing constipation medications that can be used in combination include osmotic laxatives classified as saline laxatives such as magnesium oxide or sugar laxatives such as lactulose, bulk-forming laxatives such as polycarbophil calcium, stimulant laxatives such as sennoside or sodium picosulfate, osmotic laxatives such as dioctyl sodium sulfosuccinate, serotonin 4 (5-HT4) receptor agonists such as mosapride, and type-2 chloride channel (ClC-2) agonists such as lubiprostone.

[0132] Examples of drugs currently under development that can be used in combination include guanylate cyclase receptor agonists such as linaclotide, opioid receptor antagonists such as methylnaltrexone, IBAT inhibitors such as elobixibat, SGLT1 inhibitors such as KWA-0711, serotonin 4 (5-HT4) receptor agonists such as DSP-6952, and GPR38 agonists such as DS-3801.

[0133] Compound [1] can prevent or treat hypertension by inhibiting sodium absorption in the intestinal tract and excreting sodium in the feces. Here, hypertension includes essential hypertension, secondary hypertension, and salt-sensitive hypertension. It is also considered useful as a drug that mimics salt restriction.

[0134] Compound [1] can prevent or treat nephropathy by inhibiting sodium absorption in the intestinal tract. Here, nephropathy includes diabetic nephropathy, glomerulonephritis, nephrosclerosis, and polycystic kidney disease.

[0135] Compound [1] inhibits sodium absorption in the intestinal tract and enhances sodium excretion in the feces and fluid excretion, thereby preventing or treating fluid retention. Here, fluid retention includes fluid retention due to renal failure, fluid retention due to heart failure, fluid retention due to cirrhosis of the liver, and fluid retention due to drugs.

[0136] Therefore, compound [1] can be used in combination with existing antihypertensive drugs, nephropathy drugs, and existing or under-development drugs that improve fluid retention, which have mechanisms of action other than NHE3 inhibition. By combining compound [1] with other drugs, a more potent pharmacological effect can be expected when used in combination than when each drug is used alone.

[0137] Examples of existing antihypertensive drugs, nephropathy drugs, heart failure drugs, and drugs that improve fluid retention that can be used in combination with the above-mentioned drugs include angiotensin II receptor antagonists such as candesartan, angiotensin-converting enzyme inhibitors such as lisinopril, aldosterone receptor antagonists such as eplerenone, renin inhibitors such as aliskiren, calcium channel antagonists such as amlodipine, diuretics such as thiazide diuretics and loop diuretics, alpha and beta blockers such as carvedilol, and potassium channel blockers such as amiodarone.

[0138] Examples of drugs currently under development that can be used in combination with the above include endothelin receptor antagonists such as atrasentan, PKC inhibitors such as ruboxystaurin, CCR2 receptor antagonists such as BMS-741672, aldosterone receptor antagonists such as BAY-94-8862, urotensin receptor antagonists such as ACT-058362, phosphodiesterase inhibitors such as PF-489791, NEP / ECE inhibitors such as daglutrill, TGF beta antibodies such as LY-2382770, glycation reaction inhibitors such as aminoguanidine, Keep1-Nrf2 activators such as bardoxolone methyl, VAP-1 inhibitors such as ASP-8232, aldosterone synthase inhibitors, intestinal trypsin inhibitors, LPA receptor antagonists, epoxide hydrolase inhibitors, and EP4 receptor antagonists.

[0139] Furthermore, compound [1] is expected to suppress the progression of diabetic nephropathy when combined with antidiabetic drugs or drugs under development.

[0140] Examples of diabetes medications that can be used in combination include insulin preparations, α-glucosidase inhibitors such as acarbose, SGLT2 inhibitors such as luseogliflozin, biguanides such as metformin, insulin secretagogues such as mitiglinide, dipeptidyl peptidase IV inhibitors such as sitagliptin, GLP-1 receptor agonists such as liraglutide, PPARγ agonists such as pioglitazone, and aldose reductase inhibitors such as epalrestat.

[0141] Examples of drugs currently under investigation that can be used in combination include glucokinase activators such as PF-04937319, glucagon receptor antagonists such as MK-0893, GLP-1 receptor agonists such as TTP054, amyrin agonists such as plumrintide, 11-beta-HSD1 inhibitors such as INCB-13739, GPR40 receptor agonists such as TAK-875, ACC inhibitors such as PF-05175157, GPR119 receptor agonists such as PSN-821, GPR120 receptor agonists such as LC-540449, TGR5 receptor agonists such as SB-756050, aldose reductase inhibitors such as ranirestat, SGLT1 inhibitors such as KWA-0711, and adiponectin receptor agonists.

[0142] Furthermore, compound [1] inhibits phosphorus absorption in the intestinal tract and excretes phosphorus in the feces. Therefore, it is considered useful as a treatment for hyperphosphatemia.

[0143] Compound [1] can prevent or treat CKD-MBD by inhibiting phosphorus absorption in the intestinal tract. Here, CKD-MBD includes hyperphosphatemia, hypercalcemia, hyperparathyroidism, vascular calcification, and osteoporosis due to bone metabolic disorders.

[0144] Therefore, compound [1] can be used in combination with existing or investigational drugs for CKD-MBD that have mechanisms of action other than NHE3 inhibition. By combining compound [1] with other drugs, a more potent pharmacological effect can be expected when used in combination than when each drug is used alone.

[0145] Existing CKD-MBD treatments that can be used in combination include, for example, phosphate binders such as calcium carbonate, sevelamer hydrochloride (which may also be referred to as sevelamer hydrochloride in this specification), bixalomer, lanthanum carbonate or its hydrate (which may also be referred to simply as "lanthanum carbonate" collectively as "lanthanum carbonate" collectively as "ferric citrate" collectively as "ferric citrate" collectively as "ferric citrate" collectively as "ferric citrate"), treatments for hyperparathyroidism such as cinacalcet and falecalcitriol, and treatments for osteoporosis such as bisphosphonate preparations such as ibandronate sodium.

[0146] Examples of CKD-MBD treatments currently under investigation that can be used in combination include phosphate binders such as PA21, and drugs for treating hyperparathyroidism such as ONO-5163 and KHK7580.

[0147] Compound [1], as mentioned above, has NHE3 inhibitory activity, and this inhibitory activity is known to alter the pH environment of intestinal epithelial cells and suppress intercellular transport (see: Chemistry and Biology, 2023, 61(6), 296-301). This suppression of intercellular transport has a significant impact on the uptake of various ions and compounds, including phosphate (see: Chemistry and Biology, 2023, 61(6), 296-301 and Chemistry and Biology, 2017, 55(6), 426-433). In addition, H3 and other H + / Na + Transporters include Cl26A3, which is involved in the uptake of chloride ions. ー / HCO 3 ーIt is also known to act coupled with transporters and affect the absorption of NaCl (see: Membrane, 2011, 36(6), 293-299). As a result, inhibition of NHE3 may also affect the uptake of chloride ions, bicarbonate ions, and oxalate ions (see: Membrane, 2011, 36(6), 293-299 and WO2019 / 210103). Therefore, administration of compound [1] may be expected to prevent or treat diseases caused by these ions by limiting the absorption of, for example, calcium, chloride ions, and oxalate ions. Examples of diseases caused by calcium include hypercalcemia (see: Chemistry and Biology, 2023, 61(6), 296-301). Examples of diseases caused by chloride ions include diarrhea (see: Membrane, 2011, 36(6), 293-299). Diseases caused by oxalate ions include, for example, urolithiasis and hyperoxaluria (see Biophysics, 2024, 64(1), 25-27, and WO2019 / 210103, and the NIH (National Institutes of Health) website information "A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk." (URL: Study Details | A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk. | ClinicalTrials.gov)).

[0148] Compound [1] can be administered alone or with pharmaceutically or pharmaceutically acceptable excipients.

[0149] The compound of the present invention may be used as a pharmaceutical in any form, such as a solid composition, a liquid composition, or any other composition, and the most suitable form may be selected as needed. The pharmaceutical of the present invention can be manufactured by compounding the compound of the present invention with pharmaceutically acceptable additives. Specifically, commonly used excipients or diluents, and, if necessary, commonly used binders, disintegrants, lubricants, coatings, sugar coatings, pH adjusters, solvents, or aqueous or non-aqueous solvents may be added, and the compound can be prepared into tablets, pills, capsules, granules, powders, liquids, emulsions, suspensions, injections, etc., using common pharmaceutical manufacturing techniques. Examples of the aforementioned additives include water, lactose, dextrose, fructose, sucrose, sorbitol, mannitol, polyethylene glycol, propylene glycol, starch, corn starch, gum, gelatin, alginate, calcium silicate, calcium phosphate, cellulose, water syrup, methylcellulose, polyvinylpyrrolidone, alkyl p-hydroxybenzoate, talc, stearic acid, magnesium stearate, agar, pectin, gum arabic, glycerin, sesame oil, olive oil, soybean oil, cocoa butter, ethylene glycol, low viscosity hydroxypropyl cellulose (HPC-L), microcrystalline cellulose, carboxymethylcellulose (CMC), sodium carboxymethylcellulose (CMC-Na), and other commonly used additives.

[0150] Furthermore, compound [1] can be formulated by forming an inclusion compound with α, β, or γ-cyclodextrin or methylated cyclodextrin, etc.

[0151] The pharmaceutical product according to the present invention can be a single formulation (combination formulation) or two or more formulations obtained by separately formulating compound [1] and the aforementioned co-compatible compounds. When these compounds are separately formulated to obtain two or more formulations, each formulation can be administered simultaneously or at regular time intervals. The two or more formulations can also be administered at different rates per day. Furthermore, the two or more formulations can be administered via different routes.

[0152] If the pharmaceutical product according to the present invention is provided in two different formulations, it is highly likely that they will be administered simultaneously or at very short intervals. Therefore, it is preferable to include a statement in the package insert or sales brochure of the commercially available pharmaceutical product indicating that they should be used in combination.

[0153] In this specification, "sevelamer" refers to "sevelamer hydrochloride" (trade names: Renagel, Phosblock) or "sevelamer carbonate".

[0154] The following are examples of preparations containing compound [1]. Preparation Example 1 A granular preparation containing the following components is prepared. Components: compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof, lactose, corn starch, HPC-L. Compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof and lactose are passed through a sieve. Corn starch is passed through a sieve. These are mixed in a mixer. An aqueous solution of HPC-L is added to the mixture, kneaded, granulated (extruded granulation), and then dried. The resulting dried granules are sieved through a vibrating sieve to obtain a granular preparation.

[0155] Formulation Example 2 A powder for capsule filling containing the following ingredients is prepared. Ingredients: Compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof, lactose, corn starch, magnesium stearate. Compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof and lactose are passed through a sieve. Corn starch is passed through a sieve. These are mixed with magnesium stearate in a mixer to obtain a powder. The obtained powder can be filled into capsules.

[0156] Formulation Example 3 A capsule filling granule preparation containing the following ingredients is prepared. Ingredients: Compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof, lactose, corn starch, HPC-L. Compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof and lactose are passed through a sieve. Corn starch is passed through a sieve. These are mixed in a mixer. An aqueous solution of HPC-L is added to the mixture, kneaded, granulated, and then dried. The resulting dried granules are sieved through a vibrating sieve to obtain uniform granules. The resulting granules can be filled into capsules.

[0157] Formulation Example 4 A tablet containing the following ingredients is prepared. Ingredients: Compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof, lactose, microcrystalline cellulose, magnesium stearate, CMC-Na. Compound [1] or a pharmaceutically acceptable salt thereof or a solvate thereof, lactose, microcrystalline cellulose, and CMC-Na are sieved and mixed. Magnesium stearate is added to the mixed powder to obtain a formulation powder. This mixed powder is compressed to obtain tablets.

[0158] When compound [1] is used as an NHE3 inhibitor or the like, compound [1] may be administered orally as is. Alternatively, compound [1] may be administered orally as a preparation containing it as an active ingredient.

[0159] When compound [1] is used as a phosphorus absorption inhibitor or the like, compound [1] may be administered orally as is. Alternatively, compound [1] may be administered orally as a preparation containing it as an active ingredient.

[0160] The dosage of compound [1] varies depending on the target patient, route of administration, target disease, symptoms, etc., but for example, when administered orally to an adult patient, the usual single dose is 0.1 mg to 1000 mg, preferably 1 mg to 200 mg, and it is desirable to administer this amount once to three times a day, or once every two to three days.

[0161] The present invention will be described in more detail below with reference to examples and test cases, but the present invention is not intended to be limited by these descriptions. The yields in the following examples are affected by the reaction conditions, and it is possible to achieve even higher yields by selecting optimized reaction conditions.

[0162] The instrumental analysis data described in this example were measured using the following instruments: High-performance liquid chromatography (HPLC): Prominence (Shimadzu Corporation) was used unless otherwise specified in the example. Otherwise, Agilent 1100 (Agilent). Mass spectrometry (MS): LCMS-IT-TOF (Shimadzu Corporation); Ionization method ESI / APCI

[0163] For naming compounds, software such as ACD / Name 2020 (Advanced Chemistry Development Inc.) may be used.

[0164] Example 1-1 (1) Preparation of (4S)-4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline (2S,3S)-(+)-dibenzoyl-D-tartrate monoethanol monohydrate (compound [2-f'])

[0165] 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline (compound [2-a]) (339.7 g) was mixed with ethanol (5400 g), heated to 70°C, and the solid was dissolved. Then, water (339.7 g) and (+)-dibenzoyl-D-tartaric acid (328.0 g) were added and the mixture was stirred at 70°C. The heat source was turned off, and a small amount of compound [2-f'] was added as a seed crystal at 48°C. The mixture was stirred overnight at room temperature. After stirring at 0°C for 2 hours and confirming the precipitate, the precipitate was filtered from the suspension, and the resulting wet crystals were dried to obtain the compound [2-f'] (278.6 g, 98.7% ee) as described in the title.

[0166] The HPLC retention time for the compound [2-f'] was approximately 11.7 minutes. HPLC measurement was performed using an Agilent 1100 instrument, a Daicel Chiralpak IA-3 column (4.6 mmφ × 250 mm, 3 μm), a column temperature of 40°C, a flow rate of 0.4 mL / min, a detection wavelength of 210 nm (UV), and a mobile phase of hexane / isopropanol = 10 / 90, retained for 15 minutes. MS (ESI / APCI Dual) m / z: [370.0 (M + H) +]

[0167] Furthermore, when the filtrate obtained above was allowed to stand at room temperature, a precipitate was observed. This precipitate was filtered off from the suspension, and (4R)-4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline (2S,3S)-(+)-dibenzoyl-D-tartrate (compound [2-i]; 170.8 g, 99.6% ee), which is not the target optical isomer, was also obtained.

[0168] The HPLC retention time for compound [2-i] was approximately 9.6 minutes. HPLC measurement was performed using an Agilent 1100 instrument, a Daicel Chiralpak IA-3 column (4.6 mmφ × 250 mm, 3 μm), a column temperature of 40°C, a flow rate of 0.4 mL / min, a detection wavelength of 210 nm (UV), and a mobile phase of hexane / isopropanol = 10 / 90, retained for 15 minutes. MS (ESI / APCI Dual) m / z: [370.0 (M + H) +]

[0169]

[0170] The obtained compound [2-f'] can be converted to compound [2-b] by a conventional method (see, for example, Example 2 described below).

[0171] (2) Preparation of 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline (racemic compound [2-a]) (racemization reaction of (4R)-4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline (compound [2-c]))

[0172] To the compound [2-i] (2.0 g, 99.6% ee) obtained in (1) above, which is not the target optical isomer, toluene (2.0 g, 99.6% ee), water (4.0 g), and potassium carbonate (0.70 g) were added and the mixture was stirred at room temperature for 1 hour. After removing the aqueous layer, the organic layer was washed with 10% aqueous sodium chloride solution. The organic layer was dried over sodium sulfate, filtered, and the filtrate was concentrated to obtain compound [2-c]. To the obtained compound [2-c], ethanol (16 mL), water (0.90 g), and potassium hydroxide (1.4 g) were added and the mixture was stirred overnight at 80°C. After cooling to room temperature, the precipitate was filtered off from the suspension, and the resulting wet material was dried under reduced pressure at room temperature to obtain the target racemic compound [2-a] (0.86 g).

[0173] The HPLC retention times for compound [2-a] were approximately 9.6 minutes and 11.7 minutes. HPLC measurements were performed using an Agilent 1100 instrument, a Daicel Chiralpak IA-3 column (4.6 mmφ × 250 mm, 3 μm), a column temperature of 40°C, a flow rate of 0.4 mL / min, a detection wavelength of 210 nm (UV), and a mobile phase of hexane / isopropanol = 10 / 90, retained for 15 minutes. MS (ESI / APCI Dual) m / z: [370.0 (M + H) +]

[0174] Example 1-2 Compound [2-c] was obtained under the same conditions as in Example 1-1(2), and then 1,3-dimethylbenzene was added to obtain a solution of compound [2-c]. The solution was divided into two parts, and the racemization reaction of compound [2-c] was carried out under conditions where potassium hydroxide was added as the base and under conditions where sodium tert-pentoxide was added as the base. Details are shown below. (1) To compound [2-i] (2.0 g, 99.6% ee), which was not the target optical isomer obtained in Example 1-1(1) above, toluene (8.0 g), water (4.0 g), and potassium carbonate (0.70 g) were added, and the mixture was stirred at room temperature for 1 hour. After removing the aqueous layer, the organic layer was washed with 10% aqueous sodium chloride solution. The organic layer was dried over sodium sulfate, filtered, and the filtrate was concentrated to obtain compound [2-c] (0.94 g). 1,3-dimethylbenzene (9.4 g) was added to the obtained compound [2-c], and the mixture was divided into two parts. (2) Potassium hydroxide (1.4 g) was added to one of the solutions obtained in (1) above, and the mixture was stirred at 120°C for 17 hours. The resulting compound was confirmed to be the target racemic compound [2-a]. (3) Sodium tert-pentoxide (2.78 g) was added to the other solution obtained in (1) above, and the mixture was stirred at 120°C for 17 hours. The resulting compound's optical purity decreased to 82.4% ee, confirming that the racemization reaction was proceeding.

[0175] Example 1-3 In Example 1-1(2) described above, instead of performing the liquid-liquid separation operation with potassium carbonate on compound [2-i], potassium hydroxide, ethanol, and water were added to compound [2-i] and heated to carry out the racemization reaction. Details are shown below.

[0176] To compound [2-i] (2.0 g, 99.6% ee), which was not the target optical isomer, ethanol (32 g), water (2.0 g), and potassium hydroxide (1.4 g) were added and the mixture was stirred overnight at 80°C. The resulting compound was confirmed to be the target racemic compound [2-a] by the same analytical conditions as in Example 1-1. Subsequently, the reaction solution was concentrated and substituted with toluene, washed three times with water, and then washed again with a 10% sodium chloride aqueous solution. The organic layer was dried with sodium sulfate, then the solvent was substituted with ethanol and the solution was concentrated. Ethanol was added to the resulting residue to adjust the volume of the solution to 19 mL, and water (0.94 g) and (+)-dibenzoyl-D-tartaric acid (0.90 g) were added at room temperature. The mixture was heated in an oil bath to an internal temperature of 58°C, the power to the heat source was turned off, and seed crystals were added at an internal temperature of 52°C and stirred overnight. The precipitate was filtered off, and the resulting crystals were dried under reduced pressure. The target compound [2-f'] (0.83 g, 98.6% ee) was obtained.

[0177] Example 1-4 In the same conditions as in Example 1-3 described above, potassium ethoxide was used instead of potassium hydroxide to carry out the racemization reaction of compound [2-c]. Details are shown below. Compound [2-i] (1.0 g) was mixed with ethanol (16 g) and potassium ethoxide (0.90 g) and heated at 80°C. Ethanol (16 g) was added and heated at 73°C for 20 hours. The optical purity of the resulting compound decreased to 14.9% ee, confirming that the racemization reaction was proceeding.

[0178] Example 2: Preparation of (4S)-6,8-dichloro-2-methyl-4-(3-{(trimethylsilyl)ethynyl}phenyl)-1,2,3,4-tetrahydroisoquinoline L-tartrate (compound [2-d'])

[0179] (1) A solution containing compound [2-b] was obtained by liquid-liquid extraction of compound [2-f'] (40.00 g) obtained in Example 1-1 (1). (2) Triethylamine (74.02 g), trimethylsilylacetylene (7.92 g), tetrakis(triphenylphosphine)palladium (1.17 g), and copper iodide (0.385 g) were added to the solution of compound [2-b] obtained in (1) above, and degassing was performed. The mixture was stirred at 80°C under an argon gas atmosphere. After stirring for about 2.5 hours, the power to the heat source was turned off, 3-mercaptopropyl silica gel (4.00 g) was added, and the mixture was stirred at 80-90°C for about 2 hours. After cooling to room temperature, unwanted solids were removed by filtration using Celite® as a filter aid, and the mixture was rinsed with toluene. The rinsed solution and filtrate were mixed and washed with aqueous ammonium chloride. The obtained organic layer was concentrated and replaced with isopropanol. To the concentrated and substituted solution (120 g), L-(+)-tartaric acid (9.84 g) and water (200 g) were added at 30-40°C. A seed crystal of compound [2-d'] (2.3 mg) was then added, and the mixture was cooled to 5°C. The precipitate was filtered from the suspension, and the resulting solid was washed with a mixed solution of isopropanol (8.01 g) and water (72.0 g). The resulting wet crystals were dried under reduced pressure at 45°C to obtain the compound [2-d'] (22.7 g) described in the title.

[0180] The HPLC retention time for compound [2-d'] was approximately 27.0 minutes. The HPLC measurement was performed using a YMC Triart C18 column (4.6 mmφ × 150 mm, 3 μm), with a column temperature of 40°C, a flow rate of 1.0 mL / min, and a detection wavelength of 210 nm (UV). The mobile phase consisted of a 0.1 w / v% aqueous phosphoric acid solution A and a acetonitrile solution B. The gradient conditions were as follows: A / B = 75 / 25 was reduced to 65 / 35 over 15 minutes, then to 10 / 90 over 13 minutes, held at 10 / 90 for 5 minutes, returned to 75 / 25 over 0.01 minutes, and held at 75 / 25 for 9.99 minutes. MS (ESI / APCI Dual) m / z: [388.1(M+H)+]

[0181] Example 3: Preparation of (4S)-6,8-dichloro-4-(3-ethynylphenyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (compound [2-e'])

[0182] To the compound [2-d'] (20.00 g) obtained in Example 2, methanol (108.7 g) and cyclopentyl methyl ether (49.45 g) were added at room temperature, and potassium carbonate (20.21 g) and water (19.74 g) were added under an argon gas atmosphere. The mixture was stirred for 4 hours and 40 minutes, and cyclopentyl methyl ether (246.0 g) was added. The resulting solution was sequentially washed with aqueous ammonium chloride solution (10.81 g ammonium chloride, 147.1 g water), aqueous sodium chloride solution (10.81 g sodium chloride, 97.53 g water), and water (108.03 g), and the resulting organic layer was concentrated. Isopropanol (80.70 g) was added to the concentrated solution (40.01 g). At 20–30°C, a hydrogen chloride / isopropanol solution (concentration 2 mol / L, 9.15 mL) was added, followed by the addition of another hydrogen chloride / isopropanol solution (concentration 2 mol / L, 11.0 mL). After heating to 50±5°C, the mixture was cooled to 0°C, and cyclopentyl methyl ether (207.1 g) was added dropwise. The precipitate was filtered from the suspension, and the resulting solid was washed with cyclopentyl methyl ether (59.18 g). The resulting wet crystals were dried under reduced pressure at 35–40°C to obtain the title compound [2-e'] (14.17 g).

[0183] The HPLC retention time for compound [2-e'] was approximately 19.2 minutes. The HPLC measurement was performed using a YMC Triart C18 column (4.6 mmφ × 150 mm, 3 μm), with a column temperature of 40°C, a flow rate of 1.0 mL / min, and a detection wavelength of 210 nm (UV). The mobile phase consisted of a 0.1 w / v% aqueous phosphoric acid solution A and a acetonitrile solution B. The gradient conditions were as follows: A / B = 75 / 25 was reduced to 65 / 35 over 15 minutes, then to 10 / 90 over 13 minutes, held at 10 / 90 for 5 minutes, returned to 75 / 25 over 0.01 minutes, and held at 75 / 25 for 9.99 minutes. MS (ESI / APCI Dual) m / z: [316.1(M+H)+]

[0184] Example 4: Preparation of N,N'-butane-1,4-diyrbis(N'-{2-[2-(2-hydroxyethoxy)ethoxy]ethyl}urea) (compound [3-b])

[0185] 48.40 g of amino alcohol compound [3-a] was dissolved in acetonitrile (540.0 g), and under ice cooling, a mixed solution of 1,4-diisocyanatobutane (18.00 g) and acetonitrile (90.04 g) was added. After stirring for 2.5 hours, the ice bath was removed, methanol (72.02 g) was added, and the mixture was heated to 57.3°C. The heat source was turned off and the mixture was stirred overnight. The precipitate was filtered off at room temperature, and the obtained solid was washed with a mixed solvent of acetonitrile (80.98 g) and methanol (9.01 g). The obtained solid was dried under reduced pressure at 45°C to obtain the title compound [3-b] (52.38 g).

[0186] The HPLC retention time for compound [3-b] was approximately 5.2 minutes. HPLC measurement was performed using the following conditions: Column: CAPCELL PAK CR 1:4 (4.6 mmφ × 150 mm, 5 μm), Column temperature: 40°C, Flow rate: 1.0 mL / min, Detection wavelength: 205 nm (UV), Mobile phase: Solution A: Sodium dihydrogen phosphate aqueous solution (50 mM), Solution B: Acetonitrile, Gradient conditions: Solution A / B = 90 / 10, then reduced to 5 / 95 over 30 minutes, then returned to 90 / 10 over 0.01 minutes, and held at 90 / 10 for 9.99 minutes. MS (ESI / APCI Dual) m / z: [439.3 (M + H) +]

[0187] Example 5: Preparation of N,N'-butane-1,4-diyrbis(N'-{2-[2-(2-bromoethoxy)ethoxy]ethyl}urea) (compound [3-c'])

[0188] To the diol compound [3-b] (3.00 g) obtained in Example 4, N-bromosuccinimide (3.04 g), water (24 μL), and chloroform (96.0 g) were added. To this mixture, a chloroform (42.0 g) solution of triphenylphosphine (4.49 g) was added dropwise over approximately 2 hours under ice cooling. Chloroform (6.02 g) was added dropwise to the reaction mixture in the container that had held the triphenylphosphine and chloroform. After stirring for approximately 1.5 hours, the ice cooling was removed and the mixture was stirred overnight. An aqueous sodium bicarbonate solution (1.50 g sodium bicarbonate, 28.5 g water) was added to the reaction mixture. The organic layer was separated and washed with an aqueous sodium thiosulfate solution (6.01 g sodium thiosulfate, 24.4 g water), followed by washing with water (30.0 g). The organic layer was concentrated, and acetonitrile (30.0 g) was added to the resulting residue. The solution was concentrated again, and acetonitrile (24.0 g) was added to the residue. The mixture was heated to an ambient temperature of 75°C, the heat source was turned off, and acetonitrile (2.87 g) was added. The suspension was heated to 46.7°C, then cooled to 40.5°C. Methyl tert-butyl ether (32.2 g) was added to the suspension, the heat source was turned off, and the mixture was stirred overnight. The precipitate was filtered off, and the resulting solid was washed with a mixture of acetonitrile (3.22 g) and methyl tert-butyl ether (6.45 g). The resulting solid was dried under reduced pressure at 40°C to obtain the title compound [3-c'] (3.00 g).

[0189] The HPLC retention time for compound [3-c'] was approximately 13.5 minutes. HPLC measurement was performed using a CAPCELL PAK CR 1:4 column (4.6 mmφ × 150 mm, 5 μm), column temperature: 40°C, flow rate: 1.0 mL / min, detection wavelength: 205 nm (UV), mobile phase: Solution A: aqueous sodium dihydrogen phosphate solution (50 mM), Solution B: acetonitrile, gradient conditions: Solution A / B = 90 / 10, then reduced to 5 / 95 over 30 minutes, then returned to 90 / 10 over 0.01 minutes, and held at 90 / 10 for 9.99 minutes. MS (ESI / APCI Dual) m / z: [565.1 (M+H)+]

[0190] Example 6: Preparation of N,N'-butane-1,4-diirbis(N'-{2-[2-(2-azidoethoxy)ethoxy]ethyl}urea) (3-d)

[0191] The mixture of the dibromo compound [3-c'] (9.50 g) obtained in Example 5, sodium azide (2.44 g), N-methylpyrrolidone (28.5 g), and water (2.87 g) was stirred at 75°C for about 2.5 hours, the heat source was turned off, and the mixture was stirred at room temperature overnight. The mixture was reheated and stirred at 75°C for about 4.5 hours. Ethyl acetate (143 g) and an aqueous sodium chloride solution (9.54 g sodium chloride, 42.9 g water) were added to the reaction mixture at room temperature, stirred, and then separated. The resulting aqueous layer was extracted twice with ethyl acetate (1st time: 143 g, 2nd time: 95.1 g). All of the organic layers obtained by separation were mixed and concentrated under reduced pressure, and ethanol (57.2 g) was added to the resulting residue. The mixture was concentrated again under reduced pressure, and ethanol (27.49 g) was added. An ethanol solution of the compound [3-d] mentioned in the title was obtained (the weight of the solution was 79.1 g. If the azide reaction proceeded quantitatively, the solution would contain 8.22 g of compound [3-d]). Compound [3-d] was used in the next step (Example 7) without isolation.

[0192] The HPLC retention time for compound [3-d] was approximately 19.6 minutes. The HPLC measurement was performed using the following conditions: Column: XSelect CSH Fluoro-phenyl (4.6 mmφ × 150 mm, 3.5 μm), Column temperature: 40°C, Flow rate: 1.0 mL / min, Detection wavelength: 210 nm (UV), Mobile phase: Solution A: Sodium dihydrogen phosphate aqueous solution (10 mM), Solution B: Acetonitrile, Gradient conditions: Solution A / Solution B = 87 / 13 held for 20 minutes, then reduced from Solution A / Solution B = 87 / 13 to Solution A / Solution B = 10 / 90 over 0.1 minutes, held at Solution A / Solution B = 10 / 90 for 2.9 minutes, returned to Solution A / Solution B = 87 / 13 over 0.1 minutes, and held at Solution A / Solution B = 87 / 13 for 14.9 minutes.

[0193] Example 7 (1) Preparation of 1,1'-butane-1,4-diylbis[3-(2-{2-[2-(4-{3-[(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline-4-yl]phenyl}-1H-1,2,3-triazole-1-yl)ethoxy]ethoxy}ethyl)urea][1]

[0194] Under an argon gas atmosphere, a mixture of sodium bicarbonate (0.895 g), copper(I) oxide (0.164 g), ethanol (15.9 g), and triethylamine (0.455 g) was prepared. To this mixture, an ethanol solution of compound [3-d] obtained in Example 6 (26.4 g; weighed from 79.1 g; treated as containing 2.74 g of compound [3-d]), compound [2-e'] obtained in Example 3 (4.36 g), and water (11.30 g) were added dropwise at 10-30°C. After addition, compounds [3-d] and [2-e'] adhering to the walls of the dropping funnel were rinsed with a mixture of ethanol (3.01 g) and water (3.00 g) and then added dropwise. After stirring at 10–30°C for 8 hours, 2-methyltetrahydrofuran (63.36 g), 25% aqueous ammonia (17.64 g), water (13.86 g), sodium chloride (3.18 g), and water (12.70 g) were added. After separating the two layers, the mixture was liquid-liquid, and the organic layer was washed four times with 10% aqueous sodium chloride solution (4.1 g sodium chloride, 37.0 g water), and then washed again with water (41.2 g). The mixture was concentrated and substituted with ethanol, and ethanol was added to prepare an ethanol solution (37.08 g). Acetonitrile (18.51 g) was added to the obtained solution and heated to 50°C, and acetonitrile (74.20 g) was added dropwise. The solution was cooled to 42°C, a seed crystal of compound [1] (12.7 mg) was added, and the mixture was cooled to 26°C. The precipitate was filtered from the suspension, and the resulting solid was washed with a mixture of ethanol (6.18 g) and acetonitrile (18.51 g), followed by washing with acetonitrile (30.92 g) to obtain wet crystals. The obtained wet crystals were dried under reduced pressure at room temperature to obtain the compound [1] (5.33 g) as white crystals.

[0195] The HPLC retention time for compound [1] was approximately 18.2 minutes. The HPLC measurement was performed using a YMC Triart C18 column (4.6 mmφ × 150 mm, 3 μm), with a column temperature of 40°C, a flow rate of 1.0 mL / min, a detection wavelength of 210 nm (UV), and mobile phases: Solution A 0.1 w / v% aqueous phosphoric acid solution, Solution B acetonitrile. The gradient conditions were as follows: Solution A / Solution B = 75 / 25, then reduced to 65 / 35 over 15 minutes, then reduced to 10 / 90 over 13 minutes, held at 10 / 90 for 5 minutes, returned to 75 / 25 over 0.1 minutes, and held at 75 / 25 for 9.9 minutes. MS (ESI / APCI Dual) m / z: [1119.4 (M+H)+]

[0196] (2) Compound [1] (2.00 g) and (L)-(+)-tartaric acid (0.67 g) obtained in (1) above were dissolved in methanol (21.0 g) and methyl acetate (12.0 g) and added dropwise to ethyl acetate (500 g) cooled in an ice bath. The precipitate was filtered from the suspension under a glove box and the obtained solid was washed with cooled ethyl acetate (336 g). The obtained wet material was dried under reduced pressure at 60°C to obtain (L)-(+)-tartarate (2.27 g) of compound [1] as an amorphous material.

[0197] (3) The (L)-(+)-tartrate of compound [1] could also be obtained by the following method. The compound [1] (1.0 g) and (L)-(+)-tartaric acid (0.28 g) obtained in (1) above were dissolved in a methanol-water mixture (10:1 v / v) (25 g), and the solution was dried by spraying it with a spray dryer. The resulting powder was dried to obtain the (L)-(+)-tartrate of compound [1] in amorphous form.

[0198] Furthermore, compound [A] can be produced using compound [2-b] obtained by the present invention, for example, according to the method described in WO2010 / 078449.

[0199]

[0200] Details are explained below.

[0201]

[0202] Production of Compound [A-2]: A xylene solution of potassium carbonate (0.50 equivalents relative to Compound [A-1]) is placed in a 3-neck round-bottom flask that has been purged and maintained under an inert gas atmosphere. Next, phenylmethanethiol (1.50 equivalents relative to Compound [A-1]) is added dropwise thereto while stirring at 0°C. The resulting solution is stirred at 25°C for 1 hour. A xylene solution of Compound [A-1], Pd 2 (dba) 3 (catalytic amount), and Xantphos (the same weight as Pd 2 (dba) 3 ) are added to another 3-neck round-bottom flask that has been purged and maintained under an inert gas atmosphere. The resulting solution is stirred at 25°C, and then added to the above reaction solution. The mixture is stirred at 140°C overnight. The resulting mixture can be purified to produce the title Compound [A-2].

[0203]

[0204] Production of Compound [A-3]: A solution of Compound [A-2] (1.00 equivalent) in acetic acid / water (10 / 1 v / v) is placed in a 3-neck round-bottom flask. Chlorine (gas) is introduced, and the resulting solution is stirred at room temperature. The resulting mixture can be purified to produce the title Compound [A-3].

[0205]

[0206] Production of Compound [A-4]: To a 3-neck round-bottom flask are added 2-(2-(2-aminoethoxy)ethoxy)ethanamine (21.09 equivalents relative to Compound [A-3]) and dichloromethane. Next, a DMF solution of Compound [A-3] is added dropwise thereto while stirring. The resulting solution is stirred, at which point it is diluted with ethyl acetate. The resulting mixture is washed successively twice with water and then with brine. The organic layer is dried over anhydrous sodium sulfate and concentrated under reduced pressure. Thereby, Compound [A-4] can be produced.

[0207] Preparation of N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosan-1,26-diyl)bis(3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline-4-yl)benzenesulfonamide) (compound [A]):

[0208]

[0209] To a DMF solution of compound [A-4], add 1,4-diisocyanatobutane (0.5 equivalents relative to compound [A-4]), then diisopropylethylamine (2.0 equivalents relative to compound [A-4]). Stir at room temperature, then purify the reaction product to produce compound [A] of the title.

[0210] Furthermore, the obtained compound [A] can be converted by conventional methods to its solvate, or to various pharmaceutically acceptable salts or their solvates. The converted solvates or salts can also be converted by conventional methods to crystalline or amorphous forms.

[0211] The usefulness of compound [1] can be explained, for example, by the following test example. Similarly, the usefulness of compound [A] can also be explained, for example, by the following test example.

[0212] The NHE3 inhibitory effect of compound [1] was measured using the method described in Test Example 1 below. Test Example 1

[0213] (1) Preparation of endogenous NHE-deficient cell lines Endogenous NHE-deficient cell lines were prepared using marsupial kidney (OK) cells (ATCC) according to the method of Jacques Pouyssegur et al. (Proc. Natl. Acad. Sci. USA. 1984 Vol. 81. 4833-4837).

[0214] (2) Construction of expression plasmid and human NHE3 stable expression cell line The expression plasmid was constructed by inserting the human NHE3 (SLC9A3, Accession No. NM_004174) cDNA sequence (Genecopia) into the pcDNA3.2 / V5-DEST vector (Life Technologies). The constructed human NHE3 expression plasmid was introduced into endogenous NHE-deficient OK cells to produce stable expression cells. Gene introduction was performed by electroporation using a Nucleofector 2b instrument (Lonza). Stable expression cell lines were isolated by selection in a medium containing Geneticin (Life Technologies) 500 μg / mL.

[0215] (3) NHE3 activity measurement method using NHE3 inhibition test cells: Activity was determined by the recovery of intracellular pH via NHE3 after intracellular acidification. Intracellular pH was measured using a modified version of the pH-sensitive fluorescent indicator method reported by Tsien et al. (Proc. Natl. Acad. Sci. USA., 1984, 81, 7436-7440). Human NHE3 stable expression cell lines were seeded in poly-D-lysine coated 96-well plates (Greiner) and grown overnight. The culture medium was aspirated from the wells, and the cells were heated in Hanks equilibrium salt buffer (137 mM NaCl, 20 mM HEPES, 5.6 mM glucose, 5.3 mM KCl, 1.3 mM CaCl). 2 , 0.5mM MgCl 2 , 0.4mM MgSO 4 , 0.4 mM KH 2 PO 4 , 0.3 mM Na 2 HPO 4 After washing once with pH 7.4, Hanks equilibrium salt buffer containing 0.25 μM BCECF-AM (Dojin Chemical Co., Ltd.) was added and incubated at 37°C for 30 minutes. The liquid was aspirated from the wells and NH 4 Cl buffer (20mM NH 4 Cl, 115 mM Choline chloride, 20 mM HEPES, 5 mM Glucose, 4.7 mM KCl, 1.25 mM CaCl 2 , 1.25mM MgCl 2 After adding pH 7.4, the mixture was incubated at 37°C for 10 minutes.4 Cells incubated in Cl buffer are subjected to NH 4 Cl-free buffer (133.8 mM choline chloride, 10 mM HEPES, 5 mM glucose, 4.7 mM KCl, 1.25 mM CaCl) 2 , 1.25mM MgCl 2 , 0.97 mM K 2 HPO 4 , 0.23 mM KH 2 PO 4 The intracellular pH was lowered by washing with NH (pH 7.4). After the washing process, 4 70 μL of a test compound solution prepared with a Cl-free buffer was added to the cells, and the 70 μL sodium ion-containing buffer (133.8 mM NaCl, 10 mM HEPES, 5 mM glucose, 4.7 mM KCl, 1.25 mM CaCl) was measured in the FDSS6000 analyzer (Hamamatsu Photonics). 2 , 1.25mM MgCl 2 , 0.97 mM Na 2 HPO 4 , 0.23mM NaH 2 PO 4 The recovery of pH was initiated by adding (pH 7.4). The recovery of intracellular pH was monitored by BCECF fluorescence (excitation wavelength 480 nm, fluorescence wavelength 520-560 nm), and the initial rate of pH recovery was plotted. The maximum recovery was defined as the pH recovery without the test compound, and the concentration of the test compound required to suppress this maximum recovery by 50% was defined as IC50. 50 It was calculated as a value.

[0216] (4) Results The human NHE3 inhibitory activity (nM) of compound [1] is shown in Table 1 below.

[0217]

[0218] The phosphorus absorption inhibitory effect of a compound can be evaluated according to known methods, such as the method described in Test Example 2.

[0219] The phosphorus absorption inhibitory effect of compound [1] was measured using the method described in Test Example 2 below. Test Example 2

[0220] (1) In SD rats32 Phosphate absorption inhibitory effect of compound [1] in oral phosphate loading test. Eight-week-old SD male rats (Nippon SLC Co., Ltd.) were used as experimental animals. The test compound was suspended or dissolved in Japanese Pharmacopoeia Water for Injection (Hikari Pharmaceutical Co., Ltd.) to a concentration of 0.2 mg / mL or 0.6 mg / mL and administered orally at a volume of 5 mL / kg body weight. The control group was administered the same volume of Japanese Pharmacopoeia Water for Injection. Five minutes after administration of the test compound and Water for Injection... 32 A phosphoric acid solution containing P-phosphoric acid (PerkinElmer) (1.3 mM NaH 2 PO 4 The test compound was administered at a dose of 5 mL / kg. Thirty minutes after administration of the phosphate solution, blood was collected from the tail vein, and the blood sample was immediately mixed with EDTA-2K (DOJINDO). Then, the plasma was recovered by centrifugation at 3000 rpm for 10 minutes at 4°C. The radioactivity in 100 μL of plasma was measured with a liquid scintillation counter and used as the phosphate absorption count. The phosphate absorption inhibition rate was calculated using the following formula, with the radioactivity in the plasma of the control group used as a control: Phosphate absorption inhibition rate (%) = (1 - phosphate absorption count of the test compound administered group / phosphate absorption count of the control group) × 100

[0221] (2) The phosphate absorption inhibition rate (%) of the resulting compound [1] (administered dose of 1 mg / kg or 3 mg / kg) is shown in Table 2 below. Note that the minimum effective dose (MED) can also be calculated by measuring the inhibition rate at multiple doses.

[0222]

[0223] The phosphorus efflux-enhancing effect of a compound can be evaluated according to known methods, such as the method described in Test Example 3.

[0224] The phosphorus efflux-enhancing effect of compound [1] was measured using the method described in Test Example 3 below. Test Example 3

[0225] (1) In SD rats 32Phosphate excretion-enhancing effect of compound [1] in oral phosphate loading test. Eight-week-old SD male rats (Nippon SLC Co., Ltd.) were used as experimental animals. The test compound was dissolved in Japanese Pharmacopoeia Water for Injection (Hikari Pharmaceutical Co., Ltd.) to concentrations of 0.006, 0.02, 0.06, or 0.2 mg / mL and administered orally at a volume of 5 mL / kg body weight. The control group was administered Japanese Pharmacopoeia Water for Injection at the same volume. Five minutes after administration of the test compound and Japanese Pharmacopoeia Water for Injection... 32 Phosphate solution containing P-phosphate (PerkinElmer) (12 mM NaH 2 PO 4 The solution was administered at a dose of 5 mL / kg. Feces excreted 48 hours after administration of the phosphoric acid solution were collected and weighed. 0.6 M hydrochloric acid was added to the fecal weight to a concentration of 50 mg / mL, and the mixture was shaken and mixed for 24 hours. After mixing, the feces were homogenized using a homogenizer and shaken for a further 48 hours or more to obtain the components contained in the feces. 32 Phosphate P was extracted. 32 Two mL of the solution from which P-phosphate was extracted was taken and centrifuged at 15,000 rpm for 10 minutes at room temperature, and the supernatant was collected. The radioactivity of 1 mL of the supernatant was measured with a liquid scintillation counter, and multiplied by the amount of hydrochloric acid added to determine the amount excreted in the feces. 32 The radioactivity of P was calculated. Furthermore, the radioactivity in 1 mL of phosphoric acid solution was measured and multiplied by the amount of phosphoric acid solution administered to obtain the radioactivity of P. 32 The radioactivity of phosphorus (P) was calculated. Then, the phosphorus excretion rate was determined using the following formula: Phosphorus excretion rate (%) = Phosphorus excreted in feces 32 Radioactivity of P / administered 32 After calculating the phosphorus efflux rate by multiplying the radioactivity of phosphorus by 100, the phosphorus efflux rate of the control group was used as a control, and the phosphorus efflux rate due to the test compound was calculated using the following formula: Phosphorus efflux rate (%) = (Phosphorus efflux rate of the test compound administration group / Phosphorus efflux rate of the control group - 1) × 100

[0226] (2) Results The percentage of phosphorus efflux enhancement at each dose of compound [1] is shown in Table 3 below. The minimum effective dose (MED) can also be calculated by measuring the inhibition rate at multiple doses.

[0227] Test Example 4

[0228] (1) Combined effect of compound [1] and phosphate binder in a hyperphosphatemia model rat Wistar rats (Nippon SLC Co., Ltd.) were fed a high-phosphate diet (1.2% phosphorus) and orally administered adenine sulfate (600 mg / kg, Tokyo Chemical Industry Co., Ltd.) for 10 days to induce hyperphosphatemia. Compound [1] (0.01%) and the phosphate binder sevelamer hydrochloride (1.5%, Chugai Pharmaceutical Co., Ltd.) were repeatedly administered to adenine-induced hyperphosphatemia model rats (9 weeks old) by mixing them into the diet, either alone or in combination, for 7 days. Wistar rats fed a normal diet (CE-2, Nippon CLEA Co., Ltd.) were used as normal controls. Blood was collected from the tail vein 7 days after administration, and plasma phosphorus concentration was measured using the p-methylaminophenol reduction method with Phospha C-Test Wako (Fujifilm Wako Pure Chemical Corporation).

[0229] Furthermore, the combined effects of the phosphorus binders lanthanum carbonate hydrate (3%, Thermo Fisher Scientific), ferric citrate hydrate (3%, Nacalai Tesque Co., Ltd.), and calcium carbonate (1.5%, Fujifilm Wako Pure Chemical Corporation) were evaluated using the same method. (2) Results The test results are shown in Figures 1 to 4.

[0230] Co-administration of compound [1] and sevelamer hydrochloride significantly reduced plasma phosphorus levels in adenine-induced hyperphosphatemia model rats. The plasma phosphorus-lowering effect of co-administration was superior to that of compound [1] alone. Similarly, the plasma phosphorus-lowering effect of co-administration was superior to that of sevelamer hydrochloride alone.

[0231] Furthermore, when lanthanum carbonate hydrate, ferric citrate hydrate, and calcium carbonate were used as phosphate binders, the plasma phosphorus concentration-lowering effect of combination administration was superior to that of each drug administered alone.

[0232] These results indicate that the combined administration of compound [1] or a pharmaceutically acceptable salt thereof, or a solvate thereof, with a phosphate binder is more useful for treating hyperphosphatemia.

[0233] The present invention provides a method for producing 1,1'-butane-1,4-diylbis[3-(2-{2-[2-(4-{3-[(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline-4-yl]phenyl}-1H-1,2,3-triazole-1-yl)ethoxy]ethoxy}ethyl)urea] represented by formula [1] or a pharmaceutically acceptable salt thereof or a solvate thereof, which is free from safety issues, can be easily scaled up, and is suitable for mass production.

Claims

1. A method comprising the steps of producing compound [2-e] and compound [3-d], wherein the obtained compound [2-e] and compound [3-d] are reacted to produce a compound represented by formula [1], a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein the step of producing compound [2-e] includes the step of reacting compound [2-c] with a base to perform racemization and produce compound [2-a]. (In the formula, Acid indicates an acid that forms a salt with an amine.) 2. The manufacturing method according to claim 1, wherein the step of producing compound [2-e] includes a step of performing optical resolution on the obtained compound [2-a] to produce compound [2-b].

3. The manufacturing method according to claim 2, wherein the step of producing compound [2-e] includes a step of converting the obtained compound [2-b] into compound [2-d]. (In the scheme, "Acid" has the same meaning as above.) 4. The manufacturing method according to claim 3, wherein the step of producing compound [2-e] includes a step of converting the obtained compound [2-d] into compound [2-e]. (In the scheme, Acid has the same meaning as above.) 5. The manufacturing method according to claim 1, wherein the step of producing compound [3-d] includes the step of reacting compound [3-c] with an azidation reagent to produce compound [3-d]. (In the scheme, X represents a halogen atom.) 6. The manufacturing method according to claim 5, wherein the step of producing compound [3-d] includes a step of reacting compound [3-b] with a halogenating reagent to convert it to compound [3-c]. (In the scheme, X has the same meaning as above.) 7. The manufacturing method according to claim 6, wherein the step of producing compound [3-d] includes a step of converting compound [3-a] to compound [3-b].

8. A compound represented by formula [2-d'] that is a tartrate salt, or a solvate thereof.

9. The compound represented by formula [3-b], its salt, or a solvate thereof.

10. A compound represented by formula [3-c] or a salt thereof, or a solvate thereof. (In the formula, X represents a halogen atom.) 11. The method for producing a compound represented by formula [1], or a pharmaceutically acceptable salt thereof, or a solvate thereof, is a tartrate salt of the compound represented by formula [1], according to claim 1.